
==== Front
Cell Death Discov
Cell Death Discov
Cell Death Discovery
2058-7716
Nature Publishing Group UK London

2168
10.1038/s41420-024-02168-z
Review Article
Targeting cell death in NAFLD: mechanisms and targeted therapies
Xu Hui-li 123
http://orcid.org/0000-0001-7470-2177
Wan Sheng-rong 123
An Ying 123
Wu Qi 12345
Xing Yi-hang 123
Deng Chen-hao 123
Zhang Ping-ping 12345
Long Yang 123
http://orcid.org/0000-0002-8623-3766
Xu Bu-tuo xu651044138@163.com

6
http://orcid.org/0000-0002-1955-181X
Jiang Zong-zhe jiangzongzhe555@swmu.edu.cn

1237
1 https://ror.org/0014a0n68 grid.488387.8 Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan PR China
2 Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, Sichuan PR China
3 Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan PR China
4 https://ror.org/0014a0n68 grid.488387.8 Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan PR China
5 Precision Pathology Diagnosis for Serious Diseases Key Laboratory of LuZhou, Luzhou, Sichuan PR China
6 The People’s Hospital of Pingyang, Wenzhou, Zhejiang PR China
7 https://ror.org/0014a0n68 grid.488387.8 Academician (Expert) Workstation of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan PR China
7 9 2024
7 9 2024
2024
10 39918 4 2024
22 8 2024
28 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Nonalcoholic fatty liver disease (NAFLD) is a group of chronic liver disease which ranges from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) and is characterized by lipid accumulation, inflammation activation, fibrosis, and cell death. To date, a number of preclinical studies or clinical trials associated with therapies targeting fatty acid metabolism, inflammatory factors and liver fibrosis are performed to develop effective drugs for NAFLD/NASH. However, few therapies are cell death signaling-targeted even though the various cell death modes are present throughout the progression of NAFLD/NASH. Here we summarize the four types of cell death including apoptosis, necroptosis, pyroptosis, and ferroptosis in the NAFLD and the underlying molecular mechanisms by which the pathogenic factors such as free fatty acid and LPS induce cell death in the pathogenesis of NAFLD. In addition, we also review the effects of cell death-targeted therapies on NAFLD. In summary, our review provides comprehensive insight into the roles of various cell death modes in the progression of NAFLD, which we hope will open new avenues for therapeutic intervention.

Highlights

Hepatocyte death is a critical event in the progression of NAFLD.

Different types of hepatocyte death participate in the occurrence and development of NAFLD, including apoptosis, necroptosis, pyroptosis and ferroptosis.

Drugs or compounds targeting the hepatocyte death signaling pathway is a potential direction for the treatment of NAFLD and needs to be further studied.

Subject terms

Inflammasome
Metabolic syndrome
Oncogenesis
The National Natural Science Foundation of China (No. 82270358), Sichuan Science and Technology Program (No.2024NSFSC0588; No.2022YFS0617) and Luzhou Science and Technology Program (No.2023JYJ027).Sichuan Science and Technology Program (NO.2023ZYD0095).issue-copyright-statement© Cell Death Differentiation Association (ADMC) 2024
==== Body
pmcFacts

The incidence of NAFLD is increasing worldwide and it has become a major chronic liver disease that poses a significant threat to public health.

Several forms of programmed cell death, including apoptosis, necroptosis, pyroptosis, and ferroptosis, play an integral role in the pathogenesis of NAFLD.

A growing body of evidence suggests that various cell death modes may serve as a promising target for the prevention and treatment of NAFLD.

Open questions

Which type of cell death mode plays a dominant role in NAFLD?

Are there other types of cell death modes such as cuproptosis that are also involved in the development of NAFLD?

Given that various cell death modes occur in different types of cells during the pathogenesis of NAFLD, what are the underlying links among them?

Introduction

NAFLD is defined as a clinicopathological syndrome that is not due to alcohol and other well-defined liver-damaging factors. The incidence of NAFLD is increasing worldwide with the rapid economic development and lifestyle changes and it has become a major chronic liver disease that poses a significant threat to public health [1]. Depending on the severity of the disease, NAFLD includes non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis. The most widely accepted pathogenesis of NAFLD/NASH is the current “multiple whammy” theory, which encompasses various factors such as genetic susceptibility, epigenetics, intrahepatocellular metabolic and signaling pathways, cellular interactions within the liver, and hepatocyte injury and death, and sheds light on the heterogeneity of NAFLD [2, 3]. The primary causative factors of NAFLD are predominantly attributed to the excessive accumulation of fatty acids in hepatocytes. This leads to lipotoxicity, oxidative stress, organelle dysfunction, and inflammatory responses, which subsequently initiate a cascade of cell death in the liver including apoptosis, necroptosis, pyroptosis, and ferroptosis, and ultimately exacerbate NAFLD progression. Hepatocyte death is a critical event in the progression of NAFLD, therefore a better characterization of hepatocyte death in NAFLD may lead to novel therapeutic.

Since the classification of cell death subroutines was updated by the Nomenclature Committee on Cell Death in 2018, cell death can be divided into accidental cell death (ACD) and regulated cell death (RCD) based on perspectives of morphology, biochemistry, and function. ACD is a process that cells exposed to very harsh environmental conditions (e.g., severe physical, chemical, or mechanical injury) disassemble in a virtually instantaneous and uncontrollable manner. RCD, also known as programmed cell death (PCD), is initiated and propagated by specific molecular mechanisms and is subject to regulation. It can be divided into several subroutines, such as apoptosis, necroptosis, pyroptosis, and ferroptosis [4, 5]. Based on accumulating evidence, RCD is closely related to the initiation and progression of NAFLD [6, 7]. Our review outlines the molecular mechanisms and processes of four major RCD subroutines related to NAFLD. The focus is on the latest advancements in targeting cell death for NAFLD therapy and the mechanisms of the various NAFLD therapies currently available, which mainly depend on different cell death modalities.

Different types of cell death in NALFD

Apoptosis

Overview of apoptosis

Apoptosis is a genetically determined process to terminates a cell’s life automatically that performs an important role in maintaining organismal homeostasis. It is characterized morphologically by chromatin condensation, cell shrinkage, and the eventual lysis of cells into apoptotic bodies through budding, which is subsequently cleared by phagocytosis. Mechanistically, the apoptotic pathways can be triggered by the exogenous or endogenous pathways [7, 8] (Fig. 1). In detail, the exogenous apoptotic pathway is typically mediated by cell surface death receptors (DRs), such as tumor necrosis factor receptor (TNFR), factor related apoptosis (Fas), TNF-related apoptosis-inducing ligand receptors (TRAIL-R), or toll-like receptors (TLRs) [7]. When bound to natural ligands, these receptors initiate an intracellular cascade reaction that results in the production of a death complex, which then activates caspase-8, followed by caspase-3/6/7 [7]. In the endogenous apoptotic pathway, various cellular stress, such as nuclear DNA damage, cytokine deprivation, endoplasmic reticulum stress (ERs), lysosomal permeabilization, and oxidative stress generate intracellular death signals to promote mitochondrial dysfunction and subsequently mitochondrial outer membrane pore formation (MOMP). Next, cytochrome c is released from the mitochondria into the cytoplasm through the mitochondrial membrane gap and binds to apoptosis protein activator-1 (Apaf-1) in the cytoplasm. And then, Apaf-1 undergoes oligomerization and activates caspase-9 to constitute an activation complex. This complex further activates downstream effector caspase-3/6/7, ultimately leading to the execution of apoptosis [8]. In the context of apoptosis, the mitochondrial pathway plays a crucial role in promoting caspase-8-dependent apoptotic signaling. Specifically, caspase-8 is involved in the cleavage of Bid, a death agonist with a BH3-interacting structural domain. This cleavage generates a truncated form of Bid, named tBid, which translocates to the mitochondria and disrupts the mitochondrial outer membrane. This disruption leads to MOMP, thereby integrating the two pathways into a final common pathway [9]. The regulation of MOMP is governed by the Bcl-2 protein family, comprising anti-apoptotic members (Bcl-2, Bcl-xL) and pro-apoptotic members (Bax, Bak). ERs can induce apoptosis through c-Jun N-terminal kinase (JNK) and C/EBP homologous protein (CHOP), thereby activating the pro-apoptotic protein Bax and disrupting mitochondrial function [10, 11].Fig. 1 Mechanism of apoptosis in NAFLD.

In NAFLD state, HFD, OA, PA, and FFA lead to hepatocyte apoptosis by inducing increased expression of death receptors, disrupting mitochondrial function, and triggering ER stress.

Apoptosis in NAFLD

Numerous studies have demonstrated that hepatocyte apoptosis plays a crucial role in the progression of NAFLD. Within the population of NAFLD patients, there is a remarkable increase in the number of TUNEL-positive hepatocytes and the level of caspase-3 activity compared to normal individuals. Various animal models of NAFLD have also shown increased levels of caspase-3/8/9 and decreased cytochrome c in mitochondria. Furthermore, the degree of hepatocyte apoptosis is positively correlated with the level of liver inflammation and the stage of fibrosis. Studies have demonstrated pharmacological inhibition or selective knockdown of caspases effectively reduces hepatic apoptosis and inhibits the development of inflammation and fibrosis [7, 12, 13]. All of this indicates that apoptosis is a significant feature for NAFLD [14, 15]. In some clinical studies, the expression of several DRs, including Fas, TRAIL-R1, TRAIL-R2, and TNF receptor 1(TNFR1), was shown to be increased in the livers of NAFLD patients [16–18]. Moreover, the TRAIL knockout mice have been found to avoid diet-induced NASH [19]. In response to free fatty acids (FFA) treatment, cell surface receptors aggregate, leading to caspase-8 recruitment and ultimately resulting in cell death. Notably, compared to the concentrations required for FFA-mediated Fas sensitization or FFA-induced lipid apoptosis, the concentrations required for TRAIL sensitization by FFA are significantly lower. This may be due to the upregulation of DR5 expression through ERs, and then the JNK-dependent mechanisms induced the hepatocyte steatosis sensitivity to TRAIL [20, 21]. In physiological conditions, JNK takes part in cell growth, survival, and death. The FFA induces JNK-dependent hepatocyte apoptosis by activating Bax expression, which triggers the mitochondrial apoptotic pathway [22]. Similarly, oleic acid (OA) treatment upregulated the expression of p-AKT, p-JNK, Bax, and caspase-3 and decreased the Bcl-2 expression in LO2 cells, indicating that OA can induce apoptosis via AKT/JNK signaling in a Bcl-2/ Bax/caspase-dependent manner under stress conditions. This apoptotic mode is associated with mitochondrial dysfunction, as OA treatment causes disruption of mitochondrial membrane potential. Consequently, the impairment of mitochondrial function hinders the process of fatty acid β-oxidation, leading to intracellular fatty acid accumulation which, in turn, stimulates reactive the production of reactive oxygen species (ROS), and excessive ROS further aggravates mitochondrial dysfunction, ultimately triggers apoptosis [23]. In AML-12 cells, the upregulation of Bax, caspase-3, and caspase-9 expressions, as well as the increased apoptosis rate, were observed upon exposure to palmitic acid (PA) [24]. In vivo experiments have demonstrated a significantly increase in caspase-3/9 and Bax expression accompanied by a decrease in the expression of Bcl-2 and cytochrome c in mitochondria within hepatocytes in HFD-fed mice. These findings indicate that fatty acid can indeed promote the development of NAFLD by inducing apoptosis in hepatocytes triggered by mitochondrial dysfunction [15].

Many studies have shown that excessive lipid accumulation in hepatocytes can lead to apoptosis caused by ERs. In HFD-fed mice and OA-treated hepatocytes, the endoplasmic reticulum exhibits significantly swelling and dilation. Additionally, the expression of glucose regulated protein 78 (GRP78) and CHOP, both key hallmarks of ERs, is dramatically enhanced, and the IRE1α/TRAF2/JNK signaling pathway is activated, which in turn increased the expression of Bax and inhibited the expression of Bcl-2, leading to hepatocyte apoptosis [8, 25]. Similarly, PA causes HepG2 cytotoxicity, triggers ERs through the activation of protein kinase R-like ER kinase (PERK)-eukaryotic initiation factor 2α (eIF2α) and activating transcription factor 6 (ATF6) pathways, increases the expression of ERs-associated apoptotic protein CHOP, and ultimately leads to apoptosis [26].

Therefore, in NAFLD, apoptosis appears to be the predominant form of cell death, as there is evidence for the involvement of both pathways of apoptosis. Studying the molecular mechanism of apoptosis can provide a deeper understanding of its association with NAFLD and lead to therapeutic strategies.

Apoptosis-targeted therapies in NAFLD

As a result, an increasing number of drugs have been found to alleviate NAFLD progression by targeting apoptosis (Table 1). An increasing number of studies have shown that increased levels of cellular FFA serve as a catalyst for mitochondrial oxidative damage and apoptosis. Some antioxidants, such as Selenium (Se), prevent apoptosis by improving cellular antioxidant defenses, reducing ROS production, and maintaining cellular redox homeostasis [27]. Similarly to Se, VD supplementation can also reduce oxidative stress-related indexes, which further exerts a therapeutic effect on NAFLD. Besides, HFD-induced mice supplemented with active VD showed decreased levels of P53, P21, and P16, which proved that VD inhibited hepatocyte apoptosis by inhibiting the P53 pathway, but its specific mechanism needs to be investigated [28]. Lentinan (LNT) treatment reduced the ratio of Bax/Bcl-2 protein and caspase-3 activity, ameliorated oxidative stress, and reduced lipid deposition in both PA-induced AML-12 cells and HFD-induced mouse livers. Importantly, these benefits were reversed when peroxisome proliferator-activated receptor (PPARα) was knocked down, suggesting that LNT reduces apoptosis and oxidative stress and delays the progression of NAFLD via the PPARα pathway [29]. As a polyunsaturated fatty acid (PUFA), γ-linolenic acid (GLA) not only reduces intracellular lipid deposition in hepatocytes, but also activates autophagy via the LKB1–AMPK–mTOR pathway, which in turn decreases the expression level of Bax/Bcl-2 and reduces apoptosis [24]. Hydroxycitric acid (HCA), a major component of the natural fruit Garcinia cambogia, exhibits antioxidant effects and activates the nuclear factor erythroid 2-related factor 2 (NRF2)–antioxidant response element (ARE) pathway. This activation inhibits ROS production, regulates the Bcl-2/Bax ratio and PARP cleavage, and reduces apoptosis, in both HFD-induced and FFA-induced HepG2 cells, thereby delaying the process of NAFLD [30]. In the NAFLD model of zebrafish, we observed that swimming exercise can inhibit excessive ROS production, reduce caspase-3 and Bax expression, and increase Bcl-2 levels by activating recombinant Sirtuin 1 (SIRT1)/AMP-activated protein kinase (AMPK) signaling-mediated NRF2, which in turn reduces oxidative stress and ROS-induced apoptosis in zebrafish liver, decreases lipid accumulation in zebrafish NAFLD model liver, and attenuates liver injury [31].Table 1 Apoptosis-targeted therapies in NAFLD.

Treatments	Model	Targets	Signaling pathways or molecular mechanisms	Ref.	
PinX1 knockdown	HFD-induced mice and primary mice hepatocytes	mTERT	Improves mTERT activity	[45]	
Se	Primary rat hepatocytes	Oxidative stress	Antioxidant	[27]	
Vitamin D	HFD-induced mice	Oxidative stress	Antioxidant	[28]	
Exercise	HFD-induced zebrafish	Oxidative stress	Activates SIRT1/AMPK/NRF2 signaling	[31]	
HFD-induced rat and HepG2 cells	Srit1	Activates Sirt1-mediated Drp1 acetylation	[33]	
LNT	HFD-induced mice and AML-12 cells	Oxidative stress	Activates PPARα pathway	[29]	
GLA	AML-12 cells	Oxidative stress	Activates LKB1–AMPK–mTOR pathway	[24]	
HCA	HFD-induced mice and HepG2 cells	Oxidative stress	Activates NRF2–ARE pathway	[30]	
PK	HFD-induced rat	Mitochondria	Improves mitochondrial function	[15]	
A22	HFD-induced mice and HepG2 cells	Gene promoter i-motif	Upregulates Bcl-2 transcription and translation	[32]	
BCATc inhibitor 2	LO2 and HepG2 cells	p-AKT, p-JNK, and mitochondria	Inhibits Bcl-2/Bax/caspase axis and AKT/ERK signaling and improves mitochondrial function	[23]	
EGCG	HFD-induced mice and LO2 cells	Mitochondria	Inhibits ROS/MAPK pathway	[34]	
Sulforaphane	HFD-induced mice and HepG2 cells	Ceramide	Inhibits the ceramide	[35]	
Myriocin	HFD-induced rat	Ceramide	Inhibits the ceramide	[36]	
Silicon	HFD and HSHCD-induced rat	Mitochondria	Downregulates the mitochondrial (intrinsic) pathway process	[37]	
CAR	HFD-induced mice and AML-12 cells	PRDX3	Improves mitochondrial function	[38]	
MMO	Human Chang liver cells	Mitochondria	Improves mitochondrial function	[39]	
SELENOM	HFD-induced mice and AML-12 cells	Parkin	Activates AMPKα1–MFN2 pathway and improves mitochondrial function	[40]	
Tan IIA	HepG2 cells	ER stress	Inhibits PERK/eIF2α and ATF6 signaling pathway	[26]	
Empagliflozin	HFD-induce mice	ER stress	Inhibits ER stress	[41]	
MiR-149	HFD-induced mice and primary mice hepatocytes	ER stress	Downregulates the ATF6 signaling pathway	[42]	
α-Tocopherol	HCD-induced rabbit	ER stress	Reduces JNK/c-Jun/inflammatory axis and JNK/CHOP/apoptotic signaling	[43]	
α-Linolenic acid	HFD-induced mice and HepG2 cells	AMPK	Inhibits IRE1α/TRAF2/JNK signaling pathway	[44]	

Emerging evidence indicates that mitochondrial dysfunction plays an important role in the progression of NAFLD, the dysfunctional metabolism associated with NAFLD further exacerbates mitochondrial dysfunction, thereby accelerating the development of NAFLD. However, a large number of drugs have been found to modulate mitochondrial function in a variety of ways, thereby reducing the occurrence of mitochondria-dependent apoptosis in hepatocytes and thus exerting a protective effect against NAFLD. For example, Polygonatum kingianum (PK) has been shown to improve mitochondrial function by enhancing mitochondrial ROS (MtROS) scavenging, and it reverses the upregulation of caspase-3/9 and Bax expression, while restoring the decreased levels of Bcl-2 and cytochrome c in hepatocytes of HFD-induced NAFLD rats [15]. The acridone derivative A22 has demonstrated the ability to upregulate the Bcl-2 expression and block the caspase cascade reaction and mitochondrial apoptotic pathway by selectively binding and stabilizing the Bcl-2 gene promoter i-motif. Consequently, it reduces hepatocyte apoptosis in NAFLD/NASH models and effectively attenuates liver injury [32]. It is well-accepted that aerobic exercise has shown beneficial effects in the prevention and treatment of NAFLD. In a study by Hu et al. on HFD-fed rats and OA-treated HepG2 cells, aerobic exercise regulated the acetylation and activity of dynamically related protein 1 (Drp1) by activating Sirtuins1 (Srit1). This, in turn, reduces ROS generation in hepatocytes, increases mitochondrial membrane potential, mitigates mitochondrial dysfunction, and thus prevents NAFLD [33]. Researchers have found that supplementation of branched-chain amino acids exacerbates OA-induced lipid accumulation and apoptosis. However, BCATc inhibitor 2, a branched-chain amino acid transaminase inhibitor, attenuates the OA-induced activation of JNK and AKT signaling pathways, as well as Bcl-2/Bax/caspase axis. It also reduces MtROS production and prevents potential disruption of mitochondrial membranes, thereby maintaining mitochondrial function and thus exert a protective effect against NAFLD [23]. Epigallocatechin-3-gallate (EGCG) has the potential to attenuate mitochondria-dependent apoptosis in OA-treated LO2 cells and HFD-induced mice hepatocytes by inhibiting the ROS-mediated mitogen-activated protein kinase (MAPK) pathway [34]. Saturated fatty acids (SFA) inhibited apoptosis and downregulated cleaved caspase-3 both in vitro and in vivo, and decreased ceramide and ROS levels. These findings suggest a potential preventive effect against the development of NAFLD. Specifically, ceramide, acting as a second messenger for FFA-induced apoptotic effects, can be targeted to mitigate NAFLD [35]. For instance, the ceramide synthesis inhibitor myriocin reduces the expression of p-JNK, cleaved caspase-3, Bax, and cytochrome c, while increasing the expression of Bcl-2. Additionally, it reduces hepatic lipid accumulation in the hepatocyte of NAFLD rats, leading to a significantly improvement in liver inflammation and apoptosis in NAFLD rats [36]. In a separate study, rats supplemented with silicon in the diet showed a notable reduction in the number of apoptotic cells. The levels of apoptosis-related markers such as cytoplasmic cytochrome c, apoptosis-inducing factor AIF, caspase-3/9, and Bax/Bcl-2 ratio were significantly decreased, suggesting that silicon can reduce hepatocyte apoptosis, attenuate liver injury, and affect NASH development by modulating the mitochondrial intrinsic pathway [37]. In HFD-induced mice hepatocytes and PA-induced AML-12 cells, the researchers found that carnosol (CAR) treatment can maintain mitochondrial membrane potential and inhibit mitochondrial oxidative stress by specifically interacting with and upregulating the expression of the peroxiredoxin 3 (PRDX3), a mitochondrial H2O2 scavenger. This interaction improves mitochondrial function, facilitates ROS clearance, diminishes apoptosis, mitigates liver injury, and decelerates the progression of NAFLD [38]. Huang et al. conducted a study in which they found Meretrix meretrix oligopeptides (MMO), extracted from shellfish, was able to ameliorate mitochondrial dysfunction by decreasing mitochondrial membrane potential and maintaining intracellular ion levels in PA-induced human Chang liver cells, thus exerting an anti-apoptotic effect [39]. Selenoprotein M (SELENOM) acts as an upstream inhibitor of mitochondrial damage, which regulates the pro-mitochondrial autophagy factor Parkin via the AMPKα1–Mitofusin 2 (MFN2) pathway, which in turn regulates mitochondrial membrane potential and mitochondrial autophagy, and reduces mitochondria-associated apoptosis in hepatocytes. Overexpression of SELENOM reversed the upregulation of Bax, Cyt-c, caspase-3/9 and downregulation of Bcl-2 in PA-induced AML-12 cells, attenuating the level of apoptosis. In contrast, SELENOM deficiency increased HFD-induced apoptosis and lipid accumulation in mouse hepatocytes [40].

In addition, ERs-induced apoptosis is particularly important in the progression of NAFLD, as many drugs have been found to reduce the occurrence of apoptosis in hepatocytes by inhibiting ERs. Tanshinone IIA (Tan IIA) significantly inhibited the expression of ERK-related molecules GRP78, ATF6, and CHOP in HepG2 cells induced by PA, suppressed phosphorylation of eIF2α and reduced ERs-induced apoptosis [26]. Following 5 weeks of continuous administration of the hypoglycemic drug empagliflozin in HFD-fed mice, a decrease in NAFLD activity scores (NAS) was detected. The expression of ERs molecules was significantly downregulated, resulting in an increased Bcl-2/Bax ratio, inhibited caspase-8 cleavage, and a significant reduction in hepatocyte apoptosis. It shows that empagliflozin decelerates the progression of NAFLD by reducing ERs and inhibiting hepatocyte apoptosis [41]. MiR-149 can attenuate ERs-induced apoptosis by downregulating the ATF6 signaling pathway, thereby improving NAFLD [42]. Rabbits fed a high-cholesterol diet and supplemented with α-tocopherol exhibited inhibition of cholesterol-induced NASH development. This inhibition was achieved by reducing the JNK/c-Jun/inflammatory axis and JNK/CHOP/apoptotic signaling, which may contribute to resistance against the transformation of NAFLD into NASH [43]. The α-linolenic acid phytosterol ester PS-ALA inhibits ERs by regulating the AMPK signaling pathway, which in turn inhibits the activation of IRE1α/TRAF2/JNK signaling pathway, normalizes the Bcl-2 and Bax expression, and reduces ERs-induced hepatocyte apoptosis to achieve a preventive effect against NAFLD [44].

In addition, some other drugs or molecules inhibit hepatocyte apoptosis in other ways. In HFD-induced mice and PA-treated hepatocytes, knockdown of PIN2/TRF1-interacting telomerase inhibitor 1 (PinX1) could inhibit the expression of cleaved caspase-3 and cleaved poly ADP-ribose polymerase (PARP), one of the cleavage substrates of caspase, by upregulating the expression of telomerase reverse transcriptase (mTERT), exerting an anti-apoptotic effect. While PinX1 is a potential target for the treatment of NAFLD, the specific anti-apoptotic signaling pathway and molecular mechanism remain to be investigated [45]. In a study on NAFLD rat model, long non-coding RNA HULC (lncRNA HULC) could aggravate liver injury associated with NAFLD by activating the MAPK signaling pathway. In addition, the inhibition of HULC can reduce hepatocyte apoptosis and ameliorate liver fibrosis to a certain extent in NAFLD rats, and therefore, it will serve as a potential therapeutic target for NAFLD [46].

Necroptosis

Overview of necroptosis

Necroptosis, a type of programmed inflammatory cell death, was first defined in 2005 by Degterev et al. [47] They found that the Fas/TNFR receptor family can activate a common non-apoptotic death pathway even in the absence of intracellular apoptotic signaling and it can be inhibited by specific chemical inhibitors of RIPK1, such as necrostatin-1 (Nec-1) and its modified analog Nec-1 (Fig. 2). As a result, this particular death pathway was named necroptosis. It is morphologically similar to necrosis and is characterized by increased cell volume, organelle swelling, and plasma membrane rupture [48]. The disruption of the plasma membrane leads to a rapid and extensive release of danger-associated molecular patterns (DAMPs), which subsequently trigger inflammation [49]. Although necroptosis is closely associated with apoptosis, it differs in that necroptosis is a specific type of caspase-independent cell death. Necroptosis shares the same death-inducing agents as apoptosis, including TNFα, first apoptotic signaling ligand (FasL), TRAIL, and toll-like receptor 3/4 (TLR3/4). In the context of TNF binding to TNFR1 and subsequent caspase-8 inhibition, the activation of receptor interacting protein 3 (RIPK3) triggers necroptosis [50, 51]. Active RIPK1 is recruited in an oligomeric complex including Fas-associated death domain (FADD) and caspase-8, activated caspase-8 can initiate apoptosis and also prevent necroptosis. Thus, the inhibition of caspase-8 promotes the transition from RIPK1-induced apoptosis (complex IIa) to necroptosis, where RIPK1 recruits and phosphorylates RIPK3, and activated RIPK3 further stimulates the activation of mixed lineage kinase domain-like (MLKL) through the way of phosphorylation. Phosphorylated MLKL translocates to the inner leaflet of the plasma membrane, disrupting cellular integrity and thus leading to necroptosis [52–54]. In addition, MtROS could promote necroptosis. Activated RIPK3 induces phosphorylation of MLKL and ROS production, while RIPK1 is the major target of MtROS, thus forming a positive feedback pathway for necroptosis [55].Fig. 2 Mechanism of necroptosis in NAFLD.

Various NAFLD triggering factors can lead to the upregulation of RIPK3, triggering RIPK3-dependent necroptosis, and drugs such as ELA and TTP can inhibit necroptosis and protect against NAFLD by acting on different targets of the necroptosis mechanism.

Necroptosis in NAFLD

Necroptosis has been validated to be closely associated with NAFLD and NASH in animal models and human diseases. Expression of necroptosis-associated factors MLKL, RIPK1, and RIPK3 in the liver can be used to diagnose and assess NAFLD progression [56]. Epigenetic silencing of RIPK3 in mouse and human primary hepatocytes prevents necroptosis-mediated liver pathological damage induced by MLKL activation [57]. Both RIPK3 and MLKL expression were increased in liver tissues of NAFLD and NASH patients [58, 59]. Similar to those findings, steatohepatitis was exacerbated after 18 weeks of feeding mice with a high-fat choline-deficient (HFCD) diet, and RIPK3 and MLKL were sequestrated in the insoluble protein fraction of liver lysates from NASH mice, suggesting early events during steatohepatitis progression [58]. MLKL expression in liver tissue of NAFLD patients increases in correlation with the severity of associated pathological changes, such as steatosis, ballooning, and inflammation. Compared to control mice, MLKL-KO mice fed with the HFD exhibited reduced NAS, steatosis score, inflammation, and ballooning degeneration [60]. In the methionine choline-deficient (MCD) diet-fed NASH model, the primary role of caspase-8 is to prevent excessive activation of necroptosis and caspase-8-deficient mice develop large amounts of RIPK3 in hepatocytes, leading to severe liver injury and fibrosis. Conversely, mice lacking RIP3 significantly reduced liver injury, inflammation, and fibrosis induced by the MCD diet compared to wild-type mice, indicating an important role for RIPK3-dependent necroptosis in the progression of NAFLD [61]. In contrast to HFD-fed mice, the heme oxygenase-1 (HO-1) (ROS scavenger) expression and MLKL phosphorylation were increased in sucrose-containing HFD-fed mice, while both indicators were also increased in human NAFLD patients. Excess fructose can induce NAFLD progression by enhancing OA lipotoxicity through ROS production, leading to hepatocyte necroptosis, and its effects are ameliorated by treatment with the reactive oxygen scavenger NAC [62].

RIPK3 was found to be overexpressed in the white adipose tissue (WAT) of HFCD-fed obese mice as well as in visceral WAT of obese humans, and although RIPK3 mediates necroptosis, it primarily inhibits apoptosis, which suppresses inflammation and maintains tissue homeostasis [63]. Interestingly, RIPK3 has been identified as a key mediator of necroptosis that protects mice from HFD-induced liver injury, which contrasts with previous observation in mice on the MCD diet that RIPK3 promotes NAFLD progression. The absence of RIPK3 aggravates HFD-induced liver injury, promotes hepatic inflammation and hepatocyte apoptosis, and is associated with an early fibrotic response. These findings suggest that altered patterns of hepatocyte death can influence NAFLD disease progression, where the complex balance and interplay of different pathways of PCD may be affected by the metabolic state of the liver [61, 64].

Regarding the triggering mechanism of necroptosis in the progression of NAFLD, it is speculated that it may be related to the stimulation of necroptosis-related first activation signals according to the reports. In NASH patients as well as in animal models of NAFLD, the expression of both TNF-α and TNFR1 was found to be upregulated. TNF-α levels positively correlated to the severity of liver disease, and TNFR1 deficiency exerts a protective effect against hepatic steatosis and liver damage [17, 65, 66]. Furthermore, hepatocytes are heavily exposed to TLR4 ligands during NASH [67]. When hepatocytes are exposed to these stimulatory signals, the necroptosis signaling pathway is triggered, which in turn triggers liver injury. Indeed, these necroptosis-associated signaling molecules can also stimulate apoptosis, and both necroptosis and apoptosis may be activated concurrently in liver injury, and RIPK3 can convert apoptosis to necroptosis only when caspase-8 is inhibited [51]. Whereas, with increased hepatic steatosis, the transcription factor ATF3 also increases hepatocyte death by inducing RIPK3 expression and changing the TNFα-dependent cell death pattern from apoptosis to necroptosis [68]. In exploring obstructive sleep apnea hypopnea syndrome (OSAHS)-associated NAFLD, researchers found that intermittent hypoxia (IH) increased RIPK3 upregulation caused by PA treatment of LO2 cells, promoted RIPK3-dependent necroptosis, and increases hepatic oxidative stress, and inflammatory responses. It was also found that IH-exacerbated NAFLD was regulated through the RIPK3-dependent necroptosis NRF2/nuclear factor kappa-B (NF-κB) signaling pathway [69]. Overall, we have to acknowledge the crucial role of necroptosis in the progression of NAFLD.

Necroptosis-targeted therapies in NAFLD

Researchers found that the dual peroxisome proliferator-activated receptor alpha/delta agonist Elafibranor (ELA) exerts a hepatoprotective effect by reducing cleaved RIPK3 and cleaved caspase-3, which in turn reduced hepatocyte necroptosis and apoptosis, inhibited hepatic steatosis, inflammation, and fibrosis, resulting in significantly lowered NASs [70]. RIPA-56, a specific inhibitor of RIPK1, and GSK-872, a RIPK3 inhibitor, have been shown to inhibit the RIPK1/RIPK3/MLKL pathway-mediated necroptosis. In HFD-fed mice, the use of these inhibitors targeting RIPK1/RIPK3 significantly reduces all hepatic features associated with steatohepatitis, including inflammation, liver fibrosis, transaminase activity, and triglyceride levels. Similarly, the same effect was observed by pharmacological inhibition or knockdown of the downstream MLKL of RIPK [69, 71]. In a recent report, researchers found that metformin, a commonly used medication for type 2 diabetes, activates the tristetraprolin (TTP) via the AMPK–SIRT1 pathway in hepatocytes and Kupffer cells (KCs). TTP inhibits TNF-α production in KCs, thereby reducing hepatocyte necroptosis [72]. In addition, AS1842856 attenuates necroptosis in NAFLD mice by specifically inhibiting Forkhead box O (FOXO1), a key downstream factor of the insulin/IGF-1 signaling pathway. RIPK1, RIPK3, and phosphorylated MLKL were significantly downregulated in AML-12 cells treated with AS1842856, thereby mitigating necroptosis marker protein upregulation due to PA treatment. FOXO1 is involved in the regulation of glucose metabolism, however, its role in NAFLD and its relationship with necroptosis and molecular mechanisms remain to be investigated [73].

Pyroptosis

Overview of pyroptosis

Pyroptosis was initially observed in 1992 by Zychlinsky et al. [74] in Shigella fowleri-infected macrophages and was defined as a caspase-1-dependent mode of pro-inflammatory PCD that is essential for the control of microbial infections. Pyroptosis occurs mainly during intracellular pathogen infection and is characterized by activation of the inflammasome, caspases-dependent formation of membrane pores, rupture of cell membrane swelling, and release of pro-inflammatory cytokines, such as IL-1β, IL-18, and cellular contents. These events collectively trigger subsequent immune responses to infection [75] (Fig. 3).Fig. 3 Mechanism of pyroptosis in NAFLD.

Various NAFLD triggering factors can activate canonical and non-canonical signaling pathways-induced hepatocyte death through different mechanisms. Antcin A, Dieckol, and others can inhibit pyroptosis and prevent NAFLD by acting on different targets of the pyroptosis mechanism.

Pyroptosis is activated by canonical and non-canonical signaling pathways [76]. Inflammasome activation, known as the canonical signaling pathways, involves two steps. First, the binding of danger associated molecular patterns (DAMPs), pathogen associated molecular pattern (PAMPs), or cytokines to TLRs triggers the activation of NF-κB signaling pathway, resulting in an upregulation in the expression of pro-IL-1β, pro-IL-18, and NOD-like receptor thermal protein domain associated protein 3 (NLRP3). Second, the inflammasome begin to assemble and form. DAMPs caused by environmental factors and cellular damage stimulate inflammasome sensor proteins such as NOD-like receptor proteins (NLRP1, NLRP3, NLRC4, NLRP6), absent in melanoma 2 (AIM2)-like receptors (ALRs), or pyrin families. Typical inflammasome components include the junctional protein named apoptosis-associated speck-like protein containing a CARD (ASC) and the inactive zymogen pro-caspase-1 [77, 78]. NLRP3 inflammasome activates caspase-1 to cleaves pro-IL-1β and pro-IL-18 into the active forms IL-1β and IL-18, meanwhile, cleaves the amino-terminal fragment of the key protein gasdermin D (GSDMD) to form N-GSDMD, which oligomerizes and forms membrane pore formation leading to pyroptosis and subsequent inflammatory response. In the non-canonical activation pathway of NLRP3, the presence of intracellular bacterial lipopolysaccharide (LPS) is detected by caspase-4/5/11, leading to proteolytic activation of GSDMD, which in turn leads to pyroptosis in gram-negative infections [79–81].

Pyroptosis in NAFLD

Previous studies have provided evidence supporting the involvement of pyroptosis, induced by the activation of inflammasomes, in the pathogenic mechanism of NAFLD. Hepatic mRNA levels of NLRP3, pro-caspase-1, IL-1β, and IL-18 were remarkably higher in NAFLD patients than in healthy individuals, and exhibited a strong correlation with lobular inflammation, hepatocyte ballooning, and NASs [82]. The suppression of key signaling molecules involved in the canonical signaling pathways of pyroptosis, (e.g., NLRP3, caspase-1, IL-1β, and GSDMD), was able to attenuate pathological changes such as hepatic steatosis, inflammation, and early fibrogenesis in animal models of NAFLD/NASH. This suggests the crucial role of pyroptosis in the pathogenesis of NAFLD/NASH [83–87]. During the development of NASH, activation of NLRP3 inflammasome mediates caspase-1 activation in bone marrow-derived KCs, which then release pro-inflammatory signals that can activate hepatic stellate cells (HSCs) responsible for collagen deposition and fibrosis in the liver [84]. Additionally, the internalization of NLRP3 inflammasome particles by HSCs induces their activation, resulting in increased secretion of IL-1β and expression of α-smooth muscle actin (α-SMA) [88, 89]. Over time, this process gradually leads to severe liver injury and liver fibrosis.

The first step of risk signals for inflammasome activation includes mainly DAMPs and PAMPs, leading to the activation and upregulation of NLRP3, pro-IL-1β, and pro-IL-18. The second step signals are dependent on cellular stress in the process of NAFLD/NASH including MtROS, mtDNA, ERs, and impaired mitochondrial phagocytosis, etc. [89]. Saturated FAs represent an endogenous hazards that upregulate the inflammasome in NASH in the form of a first hit and induce sensitization of hepatocytes to a second hit of LPS, resulting in the release of IL-1β [90]. Interestingly, PA activates NLRP3 inflammasome in mouse KCs by decreasing the mitochondrial membrane potential and inducing the release of mtDNA from mitochondria into the cytoplasm to form mtDNA–NLRP3 inflammasome complexes [91]. Apart from the activation of NLRP3 inflammasome in NAFLD, mitochondrial damage and mtDNA release can also trigger the activation of AIM2 inflammasome [92]. The activation of NLRC4 inflammasome is modulated by TNF-α. Increased TNF-α promotes the activation of NLRC4 inflammasome in the liver, which improves the production of IL-18 and IL-1β, triggers hepatocyte pyroptosis, and accelerates NAFLD progress [93].

Drummer et al. [94] reported that HFD-feeding increased the production of endotoxin LPS by gram-negative bacteria in the intestinal microbiota of mice. The elevated levels of LPS in circulation and intracellularly activates caspase-11 and initiates caspase-11-dependent non-canonical signaling pathways, eventually leading to pyroptosis. Additionally, PA produced by lipolysis in HFD-fed mice also activates caspase-11 and GSDMD cleavage [94]. Furthermore, the involvement of caspase-11 in mediating hepatocyte pyroptosis was verified in an MCD-induced NASH mouse model. The deficiency of caspase-11 significantly reduced liver injury and inflammation in mice, downregulated the activation of GSDMD and IL-1β, and the expression of fibrillation-related factors (TGF-β, α-SMA, and alpha-1 type I collagen) was also reduced, revealing a critical role for caspase-11 in NASH [95].

Pyroptosis-targeted therapies in NAFLD

Recent studies have shown that Exenatide treatment can effectively reduce the expression of NLRP3, caspase-1, and IL-1β in OA/LPS-induced HepG2 cells and MCD-induced db/db mouse livers, which in turn inhibits the pyroptosis signaling pathway to alleviate NASH [96]. Similarly, the herbal formulation Jinlida granule has been found to reduce the expression of NLRP3, caspase-1, IL-1β, and IL-18 in HFD-induced mouse livers as well as FFA-induced HepG2 cells, demonstrating its potential to alleviate liver injury and exert a protective effect against NAFLD by reducing hepatocyte pyroptosis [97]. However, the exact mechanism of their action remains to be studied.

Antcin A, a small triterpene molecule, indirectly inhibits pyroptosis by targeting the assembly and activation of NLRP3 inflammasome [98]. Similar to Antcin A, compounds such as Dieckol (DK), MCC950 (a specific NLRP3 inhibitor), and VD also reduce pyroptosis by targeting NLRP3 inflammasome, thereby attenuating the accumulation of triglycerides and FFA, improving liver injury, and reducing NAFLD scores [99–101]. Mangiferin (Man), on the one hand, downregulated the expression of NLRP3 inflammasome-related proteins to attenuate pyroptosis and inflammatory effects. On the other hand, it upregulates p-AMPKα levels, regulating glucolipid metabolism and ameliorating liver injury, insulin resistance, glucose tolerance, lipid accumulation, and inflammation in NAFLD mice [102]. In an As2O3-induced NASH model, researchers found that taurine (Tau) inhibits pyroptosis and attenuates hepatic inflammation through inhibition of the cathepsin B (CTSB)–NLRP3 inflammatory vesicle pathway [103]. Gardenoside, a natural botanical ingredient, ameliorates lipid accumulation and liver fibrosis by reducing the expression of pyroptosis-associated protein. The knockdown of CCCTC binding factor (CTCF) or dipeptidyl peptidase-4 (DPP4) in HFD-fed mice and PA + LPS-treated AML-12 cells yields similar effects to Gardenoside treatment, while CTCF overexpression counteracted this alteration. These findings suggest that Gardenoside inhibits via the CTCF/DPP4 signaling pathway [104]. Genipin (GNP), acting as an inhibitor of uncoupling protein-2 (UCP2), effectively reversed HFD-induced liver injury and inhibited NLRP3 inflammasome activation. Notably, its inhibitory effect on inflammasome was verified to be related to UCP2–ROS signaling [105]. Besides, lncRNA growth-arrest specific transcript 5 (GAS5) also inhibits NLRP3 inflammasome-mediated hepatocyte pyroptosis via binding miR-28a-5p in NAFLD [106].

Caveolin-1 (CAV1) may inhibit NLRP3-mediated pyroptosis through the ROS/thioredoxin-interacting protein (TXNIP) pathway. In detail, CAV1 scavenges ROS, preventing the separation of TXNIP from thioredoxin and its binding to NLRP3, thus inhibiting the assembly and activation of the NLRP3 inflammasome and attenuating liver injury [107]. Apart from CAV1, additional chemical medicines, such as Berberine (BBR) and Salvianolic acid A (SalA), have been found to inhibit pyroptosis during the NAFLD process by modulating TXNIP-induced NLRP3 inflammasome activation [108, 109]. Additionally, Liraglutide has shown promise in human and experimental studies for the prevention of NASH by inhibiting NLRP3 inflammasome activation and pyroptosis in PA + LPS-treated hepatocytes. This is achieved through the reduction of lipid accumulation, maintenance of mitochondrial function, and decrease in ROS production [110].

It was well known that, under physiological conditions, the NRF2/HO-1 axis is essential for resistance to oxidative stress, and upregulation of this axis significantly suppresses the expression of NLRP3, caspase-1, and ASC, inhibits inflammasome formation, blocks GSDMD activation, and prevents the release of IL-1β and IL-18. In exploring the mechanisms underlying the lipid-lowering and anti-inflammatory effects of Baicalin (BA), it was discovered that BA reduced FFA-induced HepG2 cells and HFD-induced mice hepatocyte pyroptosis via the NRF2/HO-1/NLRP3 pathway. However, the regulation of NRF2 by BA needs to be further investigated [111, 112]. Indeed, Danshen zexie decoction, like BA, protects against HFD-induced inflammation and liver injury by upregulating of this axis [113].

In studies of non-canonical signaling pathways, it has been found that Jiangzhi Ligan Decoction (JZLGD) ameliorated steatosis, inflammation, and pyroptosis in HFD-fed rats not only by inhibiting the NLRP3/caspase-1/GSDMD-mediated typical pyroptosis pathway but also by decreasing the levels of LPS in the hepatic portal vein of NAFLD rats, which prevented caspase-11 and GSDMD activation, inhibited the LPS/caspase-11/GSDMD-mediated non-canonical signaling pathways, and alleviated NALFD [114].

Ferroptosis

Overview of ferroptosis

Ferroptosis is a novel mode of PCD that is iron-dependent and distinct from apoptosis, necroptosis, and pyroptosis. Early in 2012, it was first described by Dixon et al. [115] and the central events of ferroptosis involve intracellular iron overload, excessive accumulation of lipid ROS, and lipid peroxidation. It differs morphologically, physiologically, and genetically from apoptosis, necroptosis, and pyroptosis, making it a unique form of cell death (Fig. 4). Morphologically, it is characterized by cell membrane rupture and effacement, a decline or even vanishment of mitochondrial cristae, mitochondrial atrophy, and normal nuclear morphology but it lacks of chromatin condensation [115].Fig. 4 Mechanism of ferroptosis in NAFLD.

Iron metabolism imbalance in the liver during NAFLD development triggers ferroptosis, leading to lipid peroxidation and accelerated NAFLD progression, and drugs such as EWCDS and BMP4 can inhibit ferroptosis and protect against NAFLD by acting on different targets of the ferroptosis mechanism.

Ferroptosis is intertwined in three aspects: amino acid and lipid metabolism, regulation of ROS, and iron regulation. As we know, the key components of the cell membrane are phospholipids (PLs), and when PUFAs are part of the membrane PLs, they become substrates for the peroxidation of cellular ferroptosis. The ferroptosis activator Erastin can act directly on systemic Xc−, the reverse transporter of cystine/glutamate in the cell membrane, to inhibit amino acid uptake, which in turn affects glutathione (GSH) synthesis, causing a decrease in glutathione peroxidase 4 (GPX4) activity [115, 116]. Under basal conditions, GPX4 converts GSH to oxidized glutathione (GSSG) and reduces cytotoxic lipid peroxides (L-OOH) to the corresponding alcohols (L-OH). In response to GPX4 inhibition, cellular antioxidant capacity is rapidly reduced, which in turn leads to the accumulation of intracellular lipid ROS, oxidative damage, and ultimately ferroptosis. Unlike the canonical ferroptosis pathway due to GPX4 inactivation, intracellular Fe2+ accumulation, which can react with peroxides in the Fenton reaction, generates excess hydroxyl radicals, induces lipid peroxidation, and drives cellular ferroptosis [117, 118]. Systemic Xc− inhibitors (e.g., Sorafenib, Sulfasalazine, and Erastin) are considered as class I ferroptosis inducers, whereas directly GPX4 inhibitors such as RAS selective lethality protein 3 (RSL3), are referred to as class II inducers [119–121]. Some transcription factors regulate ferroptosis-related genes in response to oxidative stress, for example, p53 decreases cystine uptake by inhibiting the expression of Solute carrier family 7 member 11 (SLC7A11), one of the components of the Xc− system, thereby increasing cellular susceptibility to ferroptosis [122]. And ferroptosis induced due to GPX4 deficiency can be inhibited by ferroptosis suppressor protein 1 (FSP1) through the NAD(P)H–FSP1–CoQ10 axis. This is a signaling pathway parallel to the Cyst(e)ine–GSH–GPX4 axis, which plays an important role in the inhibition of lipid peroxidation and ferroptosis [123]. In addition, there exists another pathway that inhibits ferroptosis, the GCH1–BH4–DHFR axis. Tetrahydrobiopterin (BH4), a downstream factor of GTP cyclohydrolase-1(GCH1), on the one hand, inhibits ferroptosis by promoting the synthesis of CoQ10 and, on the other hand, inhibits lipid peroxidation as an antioxidant, which, in turn, inhibits ferroptosis [124, 125].

Ferroptosis in NAFLD

Numerous studies have demonstrated the presence of iron overload in the liver tissue of NAFLD patients, that excess free iron can generate hydroxyl radicals and ROS via the Fenton reaction, promoting lipid peroxidation, and that redox imbalance is a central pathogenic mechanism of NAFLD and its progression [118, 126]. Maintaining a balance of iron metabolism in the body prevents obesity and increases insulin sensitivity, both of which are typical of NAFLD patients [127, 128]. It is estimated that one-third of patients with NAFLD present with methemoglobinemia, mainly with mild hepatic iron deposition (50–150 μmol/g) [128]. Kowdley et al. examined the connection between increased human serum ferritin (SF) and NAFLD severity, and they found that SF > 1.5 × upper limit of normal (ULN) independently predicted the development of advanced liver fibrosis in patients with NAFLD and that elevated SF was independently linked with elevated NAS even in patients without hepatic iron deposition correlated [129]. Indeed, iron metabolism disorders and ferroptosis occur in the early stages of the NAFLD process. On the one hand, in the liver of HFD-fed rats, the activity of iron regulatory protein 1 (IRP1) is increased, and it affects iron uptake and storage in cells by transcriptionally regulating the expression of ferritin, transferrin receptor-1 (TfR1) and iron export protein ferroportin (FPN-1). On the other hand, HFD induced in a time-dependent manner the expression of hepatic pro-inflammatory cytokine IL-6 and transcription factor C/EBPα, both of which promoted the expression of ferroportin, and, in turn, the downregulation of FPN-1, ultimately leading to an increase in iron content (HIC) in hepatocytes. These findings suggest a strong link between an imbalance of iron metabolism, inflammatory damage, and disease progression [130].

In addition to iron overload, lipid peroxidation is an essential process for the development of ferroptosis [131]. Loguercio et al. [132] observed that more than 90% of patients with NAFLD exhibited elevated levels of lipid peroxidation markers (malondialdehyde [MDA] and 4-hydroxynonenal [4-HNE]), and in particular, patients with NASH had significantly higher MDA and 4-HNE than patients with steatosis [132]. Qi et al. [133] demonstrated that in the MCD-induced NASH model, treatment with the GPX4 activator sodium selenite, the iron chelator desferrioxamine (DFO), and the ferroptosis inhibitor Liproxstatin-1(Lip-1) inhibited the ferroptosis, suppressed inflammatory response, and alleviated NASH, while conversely RSL3 (a ferroptosis inducer) downregulates GPX4 levels and exacerbates the severity of NASH [133]. Likewise, the presence of ferroptosis was confirmed in an arsenic-induced NASH model by detecting the expression of ferroptosis-related proteins as well as mitochondrial morphology [134]. Tsurusaki et al. [135] found that necroptosis precedes apoptosis in the process of NAFLD through a choline-deficient, ethionine-supplemented (CDE) diet model. However, after administration of necroptosis and ferroptosis inhibitors on top of the CDE diet, it was found that ferroptosis inhibitors almost completely reversed hepatocyte death, whereas necroptosis inhibitors failed to block the onset of cell death, suggesting that hepatocyte ferroptosis may be one of the initial modes of cell death at the onset of steatohepatitis and may be a trigger for the initial inflammation of steatohepatitis [135]. In summary, these studies prove that ferroptosis is involved in NAFLD and accelerates its developmental process.

Ferroptosis-targeted therapies in NAFLD

Therefore, inhibition of ferroptosis is a promising therapeutic strategy for NAFLD, and an increasing number of drugs targeting various pathways involved in the occurrence of ferroptosis have been identified, which can effectively target different ferroptosis-related factors. Consequently, these drugs inhibit ferroptosis, reduce lipid peroxidation and oxidative stress in cells, and slow down the progression of NAFLD. Notably, some ferroptosis inhibitors such as iron chelators, Fer-1, Lip-1, ROSI (ACSL4 inhibitor), and Trolox (antioxidant vitamin E analog) have been demonstrated to significantly inhibit ferroptosis in NAFLD animal models induced by arsenic, CDE-fed, MCD-fed, HFD-fed, and so on, and attenuate liver inflammation reactions, lipid accumulation, and liver injury [134–138].

In addition to some traditional iron chelators including DFO, deferiprone (DFP), and deferasirox (DFX), a novel iron nano-chelator fluorescent protein-based carbon dots (EWCDs) can effectively reduce ROS production, inhibit apoptosis, and alleviate inflammation, making EWCDs a potential treatment for zebrafish iron overload-induced NAFLD. What’s more, EWCDs can inhibit hepatocyte apoptosis and reduce inflammation by attenuating ERs [139]. Similarly, Insulin-like growth factor binding protein 7 (IGFBP7) deletion in the zebrafish NAFLD model significantly increased the expression of the nuclear receptor coactivator 4 (NCOA4), increased NCOA4-mediated ferritin autophagy (ferritinophagy), maintained intracellular iron homeostasis, and reduced the occurrence of hepatocyte ferroptosis [140]. Cilostazol inhibits ectopic erythrocyte phagocytosis by hepatic inhibition of increased platelet and erythrocyte accumulation, which in turn attenuates hepatic iron overload and prevents ferroptosis [141]. The above drugs reduce ferroptosis by directly or indirectly reducing the accumulation of Fe2+ in cells.

Accordingly, there are many other drugs that ultimately target Systemic Xc− in various ways, thereby reducing cystine uptake and inhibiting ferroptosis. The natural antioxidant arbutin (ARB) is able to target demethylase fat mass and obesity-related protein to promote methylation of the SLC7A11 gene, one of the components of Xc−, improving HFD-induced NAFLD in vivo and in vitro [142]. Icariin, a flavonoid abundant in the herb Epimedium, ameliorated MCD diet-induced lipid peroxidation, restored mitochondrial structure in the livers of NASH mice, and exerted hepatoprotective effects through the activation of Nrf2, which in turn significantly elevated the protein levels of GPX4 and a cystine/glutamate transporter (xCT) [143]. Activating transcription factor 4 (ATF4) was also able to inhibit ferroptosis and improve liver function by increasing the expression of SLC7A11 [144]. Similarly, in HFD combined with streptozotocin (STZ) injected mice and PA-treated AML-12 cells, researchers found that Puerarin treatment was able to effectively inhibit ferroptosis and reduce lipid peroxidation by activating the SIRT1/NRF2 pathway and increasing the expression of HO-1, SLC7A11, and GPX4 proteins [145]. HO-1 is the major and rate-limiting enzyme of heme metabolism, which catalyzes the catabolism of heme to biliverdin, free iron, and carbon monoxide, and HO-1 deficiency exacerbates ROS accumulation, lipid peroxidation, and iron overload in hepatocytes [146]. In FFAs-treated HepG2 cells and HFD-induced NAFLD mice, researchers found that Melatonin treatment increased NRF2 and HO-1 levels to protect cells from oxidative environment, and also upregulated the expression of GPX4 and SLC7A11 to inhibit ferroptosis [147].

In addition, in the antioxidant signaling pathway Keap1/NRF2/ARE, Gao et al. found that a substance called dehydroabietic acid binds to Keap1, activates NRF2-ARE, induces downstream gene expression, which in turn upregulates GSH, GPX4, inhibits ROS accumulation and lipid peroxidation, suppresses ferroptosis and NAFLD [148]. Yang et al. [149] found that Ginkgolide B activated the NRF2 signaling pathway by promoting NRF2 translocation to the nucleus and upregulated GPX4, which in turn inhibited ferroptosis in PA/OA-induced HepG2 cells and HFD-induced mice hepatocytes. In addition, there are a number of genes and small molecule compounds that have been shown to upregulate GPX4 through other pathways. For instance, enoyl coenzyme A hydratase 1 (ECH1) can reduce ferroptosis by upregulating GPX4 on the one hand, and reduce apoptosis by inhibiting ERK on the other hand, thus improving NAFLD [150]. In addition, PPARα inhibits ferroptosis by promoting GPX4 expression and inhibiting plasma transferrin (TRF) expression. The family of PPARs regulates energy metabolism, of which PPARα is mainly expressed in the liver and can directly induce GPX4 expression [151]. Shu et al. [152] found that time-restricted feeding suppressed the expression of the circadian gene Per2, and that specific knockdown of Per2 in hepatocytes promoted the expression of PPARα, thereby reducing lipid peroxidation levels, inhibiting the ferroptosis-related genes expression, improving mitochondrial morphology, and ultimately effectively mitigating NASH. Another novel strategy and treatment target for NAFLD identified by Zhu et al. [153] is thymosin beta 4 (Tβ4), which can exert a protective effect against NAFLD by inhibiting ferroptosis in PA-induced LO2 cells and HFD-induced rat hepatocytes through upregulation of GPX4 expression [153]. Similarly the protective effect of bone morphogenetic protein 4 (BMP4) on NAFLD is mediated by regulating GPX4 expression through a non-transcriptional mechanism. The overexpression of BMP4 in LO2 cells and HepG2 cells can upregulate the expression of GPX4, reduce ROS and MDA levels, mitigate ferroptosis, and reduce liver injury [154].

There are also drugs that inhibit ferroptosis through other pathways that also exert a protective effect against NAFLD. Quercetin can attenuate lipid droplet accumulation and lipid peroxidation, ameliorate liver injury, and alleviate NAFLD by inhibiting MtROS-mediated ferroptosis [155]. Jiang et al. [156] demonstrated that ERs are an upstream signal for ferroptosis in NAFLD, and proposed a drug, the natural flavonoid Acacetin, which inhibits ferroptosis and reduces hepatic lipid accumulation by inhibiting ERs. Liraglutide, an agonist of GLP-1R, can increase acetyl-CoA carboxylase (ACC) phosphorylation through activation of AMPK, which in turn attenuates Erastin- or RSL3-induced cellular ferroptosis in the presence of high glucose, suggesting that Liraglutide ameliorates T2DM-associated NAFLD by inhibiting ferroptosis through activation of AMPK/ACC signaling [157].

In addition to these traditional iron death drugs, Zhao et al. developed for the first time a novel nanodrug: the N-(3-triethoxysilylpropyl)gluconamide (Glu) modified magnesium silicide (Mg2Si) nanosheets (MSN-Glu), which antagonizes the free heme-induced Fenton reaction by targeting H2 delivery to hepatocytes, reduces oxidative stress, lipid peroxidation, and subsequent ferroptosis, and significantly improves hepatic metabolic function in NAFLD mice [158].

Cell death in different stages of NAFLD

NAFLD refers to a spectrum of liver damage ranging from NAFL to NASH and advanced liver fibrosis/cirrhosis. Chronic lipid accumulation in the liver causes inflammation, converts NAFL to NASH, and promotes hepatic fibrosis, with advanced progression to liver cirrhosis and hepatocellular carcinoma.

In recent years, a large number of studies have demonstrated that different types of cell death (including apoptosis, pyroptosis, necroptosis, and ferroptosis) occur concurrently in the progression of NAFL to NASH and that their occurrence correlates with the severity of the disease. Compared with patients with steatosis alone (NAFL), patients with NASH have a significantly increased level of apoptosis [12], as well as pyroptosis with elevated expression of caspase-1 [159] and necroptosis with increased expression of RIP3 [58]. In addition, the activation of HSC have been wildly reported to function in the progression of NASH to cirrhosis [160]. Notably, all the four types of cell deaths were reported to accelerate NASH by promoting HSC activation. Gaul et al. demonstrate that primary mouse and human hepatocytes can undergo pyroptosis with subsequent release of NLRP3 inflammasome proteins, which activates HSCs with increased secretion of IL-1β and α-SMA expression [159]. Human HSCs incubated with conditioned medium from steatotic hepatocytes show fibrogenic activation and enhanced resistance to apoptosis, suggesting that apoptotic hepatocytes could stimulate HSCs in patients with NASH [161]. Moreover, loss of MLKL, the terminal effector in necroptosis pathway, ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and HSC activation [162]. As to ferroptosis, it plays as a “double-edged sword” in liver fibrosis. On the one hand, hepatocyte ferroptosis can aggravate liver fibrogenesis by activating HSCs [163], while on the other hand, treatment with Erastin in mice or Sorafenib monotherapy in advanced fibrotic patients with hepatocellular carcinoma could alleviate liver fibrosis by inducing HSC ferroptosis [164, 165]. Taken together, in the stage from NAFL to NASH, levels of cell death could be used as indicators of the pathogenesis with detection of the death-related markers, whereas in the stage from NASH to cirrhosis, cell death pathways are effective therapeutic targets in blockage of HSC activation.

The cross-talk among different cell deaths in NAFLD

Given that the different types of PCD, including apoptosis, necroptosis, pyroptosis, and ferroptosis, can coexist during the pathogenesis of NAFLD, there might be extensive interactions between the different modes of cell death. PANoptosis, including apoptosis, pyroptosis, and necroptosis, is newly proposed as a coordinated cell death pathway in recent years, which has been reported to play critical roles in the pathogenesis of NAFLD [166, 167]. During infections, AIM2 regulated the innate immune sensors Pyrin and ZBP1 to drive PANoptosis and provide host protection [168]. Si-Wu-Tang, a traditional Chinese herbal prescription, was reported to protect against hepatitis-mediated hepatocyte PANoptosis through inhibiting mtDNA release-mediated ZBP1 activation [167]. In monocytes and macrophages, caspase-1 activates caspases-3/7 and induces apoptosis in the absence of GSDMD while caspases-3/7 specifically block pyroptosis by cleaving GSDMD during apoptosis, which is called “bidirectional crosstalk” [169]. Whereas in the progression of NAFL to NASH, ghrelin shows beneficial effects via inhibition of TNF-α-induced hepatocyte apoptosis and pyroptosis [170]. Sodium sulfite, a biological derivative of the air pollutant sulfur dioxide, could trigger hepatic apoptosis, necroptosis, and pyroptosis in mice and hepatocye cell line [171]. Interestingly, in a 3-week non-alcoholic steatohepatitis mouse model, Elafibranor showed strong benefits on NASH with improvement in hepatic inflammation, necroptosis, and apoptosis, but did not alter pyroptosis [172]. Tβ4, a multifunctional polypeptide, improved PA-induced LO2 damage through inhibition of apoptosis and ferroptosis. Furthermore, GPX4 knockdown attenuated therapeutic effect of Tβ4 on rat liver and LO2 cells with upregulation of apoptosis-related Bcl-2, Bax, and caspase-3 [153]. Besides, in addition to blocking the ferroptosis markers ACSL4 and ALOX15, ferroptosis inhibitor liproxstatin-1 also inhibited hepatic apoptosis, pyroptosis, and necroptosis by inhibiting cleavages of PANoptosis-related caspase-8 and caspase-6 in MAFLD mouse liver [173]. Taken together, more and more evidence regarding the interactions among apoptosis, pyroptosis and necroptosis and the relationship between panoptosis and ferroptosis is provided in pathogenesis of NAFLD interactions. However, although the ferroptosis and panoptosis are common targets of drugs, the underlying molecular mechanism is yet unknown (Fig. 5).Fig. 5 Cross-talk among different cell deaths.

The three modes of death, including apoptosis, pyroptosis, and necroptosis, which coexist in NAFLD and interact with each other, are called PANoptosis. However, the interaction between PANoptosis and ferroptosis is not yet known.

Limitations

There exist several limitations, as different cell death subroutines display distinct feature, while sharing many similar characteristics with considerable overlap and cross-talk. Though it is recognized that various types of cell death may collectively contribute to the onset and progression of NAFLD, the specific dominant role of each type and the potential synergy resulting from the simultaneous activation of multiple pathways in hepatocytes remain elusive. To date, certain cell death modes, such as cuproptosis [174], remain poorly understood, and no literature has been found on the direct association with NAFLD.

Conclusions and perspectives

This article reviews the molecular mechanisms of four different forms of cell death, demonstrates the existence of multiple forms of hepatocyte death in NAFLD and the acceleration of NAFLD progression by these forms of cell death in in vitro and in vivo experiments, and summarizes the therapeutic agents or potential therapeutic targets for the different forms of cell death in the existing studies. However, our understanding of the association between different forms of cell death and NAFLD is incomplete, and the pathophysiologic mechanisms are not yet clearly elucidated. Current studies have not yet been able to answer the question of the interrelationships and influences of the various forms of cell death in the disease, as well as the sequence and predominance of the various forms of cell death at different stages of the disease progression. Future research needs to focus on understanding the linkages between different forms of cell death pathways and their possible roles in NAFLD to help us better understand the complex mechanisms of the disease and to find more effective therapeutic agents that target cell death.

Acknowledgements

The figures were created with BioRender software (BioRender.com).

Author contributions

H-lX: conceptualization, writing—original draft. S-rW: investigation, writing—original draft. Y-A: visualization, investigation. Q-W: visualization, investigation. Y-hX: investigation, validation. C-hD: investigation, validation. P-pZ: investigation, validation. Y-L: investigation, validation. B-tX: conceptualization, writing—review & editing. Z-zJ: conceptualization, writing—review & editing.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No. 82270358), Sichuan Science and Technology Program (Nos. 2024NSFSC0588; 2022YFS0617; 2023ZYD0095), and Luzhou Science and Technology Program (2023JYJ027).

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Hui-li Xu, Sheng-rong Wan.
==== Refs
References

1. Powell EE Wong VW Rinella M Non-alcoholic fatty liver disease Lancet 2021 397 2212 24 10.1016/S0140-6736(20)32511-3 33894145
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–24.33894145 10.1016/S0140-6736(20)32511-3
2. Loomba R Friedman SL Shulman GI Mechanisms and disease consequences of nonalcoholic fatty liver disease Cell 2021 184 2537 64 10.1016/j.cell.2021.04.015 33989548
Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537–64.33989548 10.1016/j.cell.2021.04.015
3. Friedman SL Neuschwander-Tetri BA Rinella M Sanyal AJ Mechanisms of NAFLD development and therapeutic strategies Nat Med 2018 24 908 22 10.1038/s41591-018-0104-9 29967350
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.29967350 10.1038/s41591-018-0104-9
4. Galluzzi L Vitale I Aaronson SA Abrams JM Adam D Agostinis P Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Cell Death Differ 2018 25 486 541 10.1038/s41418-017-0012-4 29362479
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541.29362479 10.1038/s41418-017-0012-4
5. Tang D Kang R Berghe TV Vandenabeele P Kroemer G The molecular machinery of regulated cell death Cell Res 2019 29 347 64 10.1038/s41422-019-0164-5 30948788
Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347–64.30948788 10.1038/s41422-019-0164-5
6. Gautheron J Gores GJ Rodrigues CMP Lytic cell death in metabolic liver disease J Hepatol 2020 73 394 408 10.1016/j.jhep.2020.04.001 32298766
Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol. 2020;73:394–408.32298766 10.1016/j.jhep.2020.04.001
7. Shojaie L Iorga A Dara L Cell death in liver diseases: a review Int J Mol Sci 2020 21 9682 10.3390/ijms21249682 33353156
Shojaie L, Iorga A, Dara L. Cell death in liver diseases: a review. Int J Mol Sci. 2020;21:9682.33353156 10.3390/ijms21249682
8. Riedl SJ Shi Y Molecular mechanisms of caspase regulation during apoptosis Nat Rev Mol Cell Biol 2004 5 897 907 10.1038/nrm1496 15520809
Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5:897–907.15520809 10.1038/nrm1496
9. Li S Zhao Y He X Kim T Kuharsky DK Rabinowich H Relief of extrinsic pathway inhibition by the bid-dependent mitochondrial release of smac in Fas-mediated hepatocyte apoptosis J Biol Chem 2002 277 26912 20 10.1074/jbc.M200726200 12011074
Li S, Zhao Y, He X, Kim T, Kuharsky DK, Rabinowich H, et al. Relief of extrinsic pathway inhibition by the bid-dependent mitochondrial release of smac in Fas-mediated hepatocyte apoptosis. J Biol Chem. 2002;277:26912–20.12011074 10.1074/jbc.M200726200
10. Kale J Osterlund EJ Andrews DW BCL-2 family proteins: changing partners in the dance towards death Cell Death Differ 2018 25 65 80 10.1038/cdd.2017.186 29149100
Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80.29149100 10.1038/cdd.2017.186
11. Rao RV Ellerby HM Bredesen DE Coupling endoplasmic reticulum stress to the cell death program Cell Death Differ 2004 11 372 80 10.1038/sj.cdd.4401378 14765132
Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004;11:372–80.14765132 10.1038/sj.cdd.4401378
12. Feldstein AE Canbay A Angulo P Taniai M Burgart LJ Lindor KD Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 2003 125 437 43 10.1016/S0016-5085(03)00907-7 12891546
Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437–43.12891546 10.1016/S0016-5085(03)00907-7
13. Hatting M Zhao G Schumacher F Sellge G Al MM Gaβler N Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents Hepatology 2013 57 2189 201 10.1002/hep.26271 23339067
Hatting M, Zhao G, Schumacher F, Sellge G, Al MM, Gaβler N, et al. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. Hepatology. 2013;57:2189–201.23339067 10.1002/hep.26271
14. Barreyro FJ Holod S Finocchietto PV Camino AM Aquino JB Avagnina A The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis Liver Int 2014 35 953 66 10.1111/liv.12570 24750664
Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, et al. The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis. Liver Int. 2014;35:953–66.24750664 10.1111/liv.12570
15. Yang XX Wang X Shi TT Dong JC Li FJ Zeng LX Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: the alleviating effect and its mechanism of Polygonatum kingianum Biomed Pharmacother 2019 117 109083 10.1016/j.biopha.2019.109083 31387169
Yang XX, Wang X, Shi TT, Dong JC, Li FJ, Zeng LX, et al. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: the alleviating effect and its mechanism of Polygonatum kingianum. Biomed Pharmacother. 2019;117:109083.31387169 10.1016/j.biopha.2019.109083
16. Alkhouri N Alisi A Okwu V Matloob A Ferrari F Crudele A Circulating soluble Fas and Fas ligand levels are elevated in children with nonalcoholic steatohepatitis Dig Dis Sci 2015 60 2353 9 10.1007/s10620-015-3614-z 25764498
Alkhouri N, Alisi A, Okwu V, Matloob A, Ferrari F, Crudele A, et al. Circulating soluble Fas and Fas ligand levels are elevated in children with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:2353–9.25764498 10.1007/s10620-015-3614-z
17. Crespo J Cayón A Fernández-Gil P Hernández-Guerra M Mayorga M Domínguez-Díez A Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients Hepatology 2001 34 1158 63 10.1053/jhep.2001.29628 11732005
Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158–63.11732005 10.1053/jhep.2001.29628
18. Afonso MB Castro RE Rodrigues CMP Processes exacerbating apoptosis in non-alcoholic steatohepatitis Clin Sci 2019 133 2245 64 10.1042/CS20190068
Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci. 2019;133:2245–64.10.1042/CS20190068
19. Hirsova P Ibrahim SH Krishnan A Verma VK Bronk SF Werneburg NW Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes Gastroenterology 2016 150 956 67 10.1053/j.gastro.2015.12.037 26764184
Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology. 2016;150:956–67.26764184 10.1053/j.gastro.2015.12.037
20. Malhi H Barreyro FJ Isomoto H Bronk SF Gores GJ Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity Gut 2007 56 1124 31 10.1136/gut.2006.118059 17470478
Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007;56:1124–31.17470478 10.1136/gut.2006.118059
21. Cazanave SC Mott JL Bronk SF Werneburg NW Fingas CD Meng XW Death receptor 5 signaling promotes hepatocyte lipoapoptosis J Biol Chem 2011 286 39336 48 10.1074/jbc.M111.280420 21941003
Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286:39336–48.21941003 10.1074/jbc.M111.280420
22. Malhi H Bronk SF Werneburg W Gores GJ Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis J Biol Chem 2006 281 12093 101 10.1074/jbc.M510660200 16505490
Malhi H, Bronk SF, Werneburg W, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 2006;281:12093–101.16505490 10.1074/jbc.M510660200
23. Lu Z Sun GF Pan XA Qu XH Yang P Chen ZP BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model Front Pharmacol 2022 13 1025551 10.3389/fphar.2022.1025551 36386234
Lu Z, Sun GF, Pan XA, Qu XH, Yang P, Chen ZP, et al. BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model. Front Pharmacol. 2022;13:1025551.36386234 10.3389/fphar.2022.1025551
24. Liang Y Zhang Z Tu J Wang Z Gao X Deng K γ-Linolenic acid prevents lipid metabolism disorder in palmitic acid-treated alpha mouse liver-12 cells by balancing autophagy and apoptosis via the LKB1-AMPK-mTOR pathway J Agric Food Chem 2021 69 8257 67 10.1021/acs.jafc.1c02596 34281337
Liang Y, Zhang Z, Tu J, Wang Z, Gao X, Deng K, et al. γ-Linolenic acid prevents lipid metabolism disorder in palmitic acid-treated alpha mouse liver-12 cells by balancing autophagy and apoptosis via the LKB1-AMPK-mTOR pathway. J Agric Food Chem. 2021;69:8257–67.34281337 10.1021/acs.jafc.1c02596
25. Sozen E Ozer NK Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: an updated mini-review Redox Biol 2017 12 456 61 10.1016/j.redox.2017.02.025 28319895
Sozen E, Ozer NK. Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: an updated mini-review. Redox Biol. 2017;12:456–61.28319895 10.1016/j.redox.2017.02.025
26. Wang J Hu R Yin C Xiao Y Tanshinone IIA reduces palmitate‐induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 liver cells Fundam Clin Pharmacol 2020 34 249 62 10.1111/fcp.12510 31520549
Wang J, Hu R, Yin C, Xiao Y. Tanshinone IIA reduces palmitate‐induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 liver cells. Fundam Clin Pharmacol. 2020;34:249–62.31520549 10.1111/fcp.12510
27. Zhang Z, Li S, Jiang H, Liu B, Lv Z, Guo C, et al. Effects of selenium on apoptosis and abnormal amino acid metabolism induced by excess fatty acid in isolated rat hepatocytes. Mol Nutr Food Res. 2017;61:1700016.
28. Liu Y Wang M Xu W Zhang H Qian W Li X Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway Life Sci 2020 241 117086 10.1016/j.lfs.2019.117086 31756344
Liu Y, Wang M, Xu W, Zhang H, Qian W, Li X, et al. Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway. Life Sci. 2020;241:117086.31756344 10.1016/j.lfs.2019.117086
29. Du T Fang Q Zhang Z Zhu C Xu R Chen G Lentinan protects against nonalcoholic fatty liver disease by reducing oxidative stress and apoptosis via the PPARα pathway Metabolites 2022 12 55 10.3390/metabo12010055 35050176
Du T, Fang Q, Zhang Z, Zhu C, Xu R, Chen G, et al. Lentinan protects against nonalcoholic fatty liver disease by reducing oxidative stress and apoptosis via the PPARα pathway. Metabolites. 2022;12:55.35050176 10.3390/metabo12010055
30. Han J Park M Myung C Garcinia cambogia ameliorates non-alcoholic fatty liver disease by inhibiting oxidative stress-mediated steatosis and apoptosis through NRF2-ARE activation Antioxidants 2021 10 1226 10.3390/antiox10081226 34439474
Han J, Park M, Myung C. Garcinia cambogia ameliorates non-alcoholic fatty liver disease by inhibiting oxidative stress-mediated steatosis and apoptosis through NRF2-ARE activation. Antioxidants. 2021;10:1226.34439474 10.3390/antiox10081226
31. Zou Y Chen Z Sun C Yang D Zhou Z Peng X Exercise intervention mitigates pathological liver changes in NAFLD zebrafish by activating SIRT1/AMPK/NRF2 signaling Int J Mol Sci 2021 22 10940 10.3390/ijms222010940 34681600
Zou Y, Chen Z, Sun C, Yang D, Zhou Z, Peng X, et al. Exercise intervention mitigates pathological liver changes in NAFLD zebrafish by activating SIRT1/AMPK/NRF2 signaling. Int J Mol Sci. 2021;22:10940.34681600 10.3390/ijms222010940
32. Li X Wang J Gong X Zhang M Kang S Shu B Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH Nucleic Acids Res 2020 48 8255 68 10.1093/nar/gkaa615 32710621
Li X, Wang J, Gong X, Zhang M, Kang S, Shu B, et al. Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH. Nucleic Acids Res. 2020;48:8255–68.32710621 10.1093/nar/gkaa615
33. Hu Z Zhang H Wang Y Li B Liu K Ran J Exercise activates Sirt1-mediated Drp1 acetylation and inhibits hepatocyte apoptosis to improve nonalcoholic fatty liver disease Lipids Health Dis 2023 22 33 10.1186/s12944-023-01798-z 36882837
Hu Z, Zhang H, Wang Y, Li B, Liu K, Ran J, et al. Exercise activates Sirt1-mediated Drp1 acetylation and inhibits hepatocyte apoptosis to improve nonalcoholic fatty liver disease. Lipids Health Dis. 2023;22:33.36882837 10.1186/s12944-023-01798-z
34. Wu D Liu Z Wang Y Zhang Q Li J Zhong P Epigallocatechin-3-gallate alleviates high-fat diet-induced nonalcoholic fatty liver disease via inhibition of apoptosis and promotion of autophagy through the ROS/MAPK signaling pathway Oxid Med Cell Longev 2021 2021 5599997 10.1155/2021/5599997 33953830
Wu D, Liu Z, Wang Y, Zhang Q, Li J, Zhong P, et al. Epigallocatechin-3-gallate alleviates high-fat diet-induced nonalcoholic fatty liver disease via inhibition of apoptosis and promotion of autophagy through the ROS/MAPK signaling pathway. Oxid Med Cell Longev. 2021;2021:5599997.33953830 10.1155/2021/5599997
35. Li J Xie S Teng W Sulforaphane attenuates nonalcoholic fatty liver disease by inhibiting hepatic steatosis and apoptosis Nutrients 2021 14 76 10.3390/nu14010076 35010950
Li J, Xie S, Teng W. Sulforaphane attenuates nonalcoholic fatty liver disease by inhibiting hepatic steatosis and apoptosis. Nutrients. 2021;14:76.35010950 10.3390/nu14010076
36. Jiang M Li C Liu Q Wang A Lei M Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease Front Endocrinol 2019 10 665 10.3389/fendo.2019.00665
Jiang M, Li C, Liu Q, Wang A, Lei M. Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease. Front Endocrinol. 2019;10:665.10.3389/fendo.2019.00665
37. Garcimartín A López-Oliva ME Sántos-López JA García-Fernández RA Macho-González A Bastida S Silicon alleviates nonalcoholic steatohepatitis by reducing apoptosis in aged Wistar rats fed a high–saturated fat, high-cholesterol diet J Nutr 2017 147 1104 12 10.3945/jn.116.243204 28446627
Garcimartín A, López-Oliva ME, Sántos-López JA, García-Fernández RA, Macho-González A, Bastida S, et al. Silicon alleviates nonalcoholic steatohepatitis by reducing apoptosis in aged Wistar rats fed a high–saturated fat, high-cholesterol diet. J Nutr. 2017;147:1104–12.28446627 10.3945/jn.116.243204
38. Geng Y Wang Y Sun R Kang X Zhao H Zhu M Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3 Toxicol Appl Pharmacol 2021 432 115758 10.1016/j.taap.2021.115758 34678374
Geng Y, Wang Y, Sun R, Kang X, Zhao H, Zhu M, et al. Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. Toxicol Appl Pharmacol. 2021;432:115758.34678374 10.1016/j.taap.2021.115758
39. Huang F Zhao S Yu F Yang Z Ding G Protective effects and mechanism of meretrix meretrix oligopeptides against nonalcoholic fatty liver disease Mar Drugs 2017 15 31 10.3390/md15020031 28216552
Huang F, Zhao S, Yu F, Yang Z, Ding G. Protective effects and mechanism of meretrix meretrix oligopeptides against nonalcoholic fatty liver disease. Mar Drugs. 2017;15:31.28216552 10.3390/md15020031
40. Cai J Huang J Yang J Chen X Zhang H Zhu Y The protective effect of selenoprotein M on non-alcoholic fatty liver disease: the role of the AMPKα1–MFN2 pathway and Parkin mitophagy Cell Mol Life Sci 2022 79 354 10.1007/s00018-022-04385-0 35678878
Cai J, Huang J, Yang J, Chen X, Zhang H, Zhu Y, et al. The protective effect of selenoprotein M on non-alcoholic fatty liver disease: the role of the AMPKα1–MFN2 pathway and Parkin mitophagy. Cell Mol Life Sci. 2022;79:354.35678878 10.1007/s00018-022-04385-0
41. Nasiri-Ansari N Nikolopoulou C Papoutsi K Kyrou I Mantzoros CS Kyriakopoulos G Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(−/−) mice by activating autophagy and reducing ER stress and apoptosis Int J Mol Sci 2021 22 818 10.3390/ijms22020818 33467546
Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros CS, Kyriakopoulos G, et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(−/−) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. 2021;22:818.33467546 10.3390/ijms22020818
42. Chen Z Liu Y Yang L Liu P Zhang Y Wang X MiR-149 attenuates endoplasmic reticulum stress-induced inflammation and apoptosis in nonalcoholic fatty liver disease by negatively targeting ATF6 pathway Immunol Lett 2020 222 40 8 10.1016/j.imlet.2020.03.003 32194141
Chen Z, Liu Y, Yang L, Liu P, Zhang Y, Wang X. MiR-149 attenuates endoplasmic reticulum stress-induced inflammation and apoptosis in nonalcoholic fatty liver disease by negatively targeting ATF6 pathway. Immunol Lett. 2020;222:40–8.32194141 10.1016/j.imlet.2020.03.003
43. Demirel-Yalciner T Sozen E Ozaltin E Sahin A Ozer NK alpha‐Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis BioFactors 2021 47 403 13 10.1002/biof.1700 34101924
Demirel-Yalciner T, Sozen E, Ozaltin E, Sahin A, Ozer NK. alpha‐Tocopherol supplementation reduces inflammation and apoptosis in high cholesterol mediated nonalcoholic steatohepatitis. BioFactors. 2021;47:403–13.34101924 10.1002/biof.1700
44. Han H Xue T Li Jie Guo Y Li X Wang L Plant sterol ester of α-linolenic acid improved non-alcoholic fatty liver disease by attenuating endoplasmic reticulum stress-triggered apoptosis via activation of the AMPK J Nutr Biochem 2022 107 109072 10.1016/j.jnutbio.2022.109072 35660097
Han H, Xue T, Li Jie, Guo Y, Li X, Wang L, et al. Plant sterol ester of α-linolenic acid improved non-alcoholic fatty liver disease by attenuating endoplasmic reticulum stress-triggered apoptosis via activation of the AMPK. J Nutr Biochem. 2022;107:109072.35660097 10.1016/j.jnutbio.2022.109072
45. Huang E Xu K Gu X Zhu Q PinX1 depletion improves liver injury in a mouse model of nonalcoholic fatty liver disease via increasing telomerase activity and inhibiting apoptosis Cytogenet Genome Res 2021 161 449 62 10.1159/000518284 34657040
Huang E, Xu K, Gu X, Zhu Q. PinX1 depletion improves liver injury in a mouse model of nonalcoholic fatty liver disease via increasing telomerase activity and inhibiting apoptosis. Cytogenet Genome Res. 2021;161:449–62.34657040 10.1159/000518284
46. Shen X Guo H Xu J Wang J Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease J Cell Physiol 2019 234 18169 79 10.1002/jcp.28450 30908654
Shen X, Guo H, Xu J, Wang J. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019;234:18169–79.30908654 10.1002/jcp.28450
47. Degterev A Huang Z Boyce M Li Y Jagtap P Mizushima N Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury Nat Chem Biol 2005 1 112 9 10.1038/nchembio711 16408008
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–9.16408008 10.1038/nchembio711
48. Zong W Thompson CB Necrotic death as a cell fate Genes Dev 2006 20 1 15 10.1101/gad.1376506 16391229
Zong W, Thompson CB. Necrotic death as a cell fate. Genes Dev. 2006;20:1–15.16391229 10.1101/gad.1376506
49. Kaczmarek A Vandenabeele P Krysko DV Necroptosis: the release of damage-associated molecular patterns and its physiological relevance Immunity 2013 38 209 23 10.1016/j.immuni.2013.02.003 23438821
Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209–23.23438821 10.1016/j.immuni.2013.02.003
50. Weinlich R Oberst A Beere HM Green DR Necroptosis in development, inflammation and disease Nat Rev Mol Cell Biol 2017 18 127 36 10.1038/nrm.2016.149 27999438
Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2017;18:127–36.27999438 10.1038/nrm.2016.149
51. Schwabe RF Luedde T Apoptosis and necroptosis in the liver: a matter of life and death Nat Rev Gastroenterol Hepatol 2018 15 738 52 10.1038/s41575-018-0065-y 30250076
Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15:738–52.30250076 10.1038/s41575-018-0065-y
52. Linkermann A Green DR Necroptosis N Engl J Med 2014 370 455 65 10.1056/NEJMra1310050 24476434
Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370:455–65.24476434 10.1056/NEJMra1310050
53. Wang H Sun L Su L Rizo J Liu L Wang LF Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3 Mol Cell 2014 54 133 46 10.1016/j.molcel.2014.03.003 24703947
Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54:133–46.24703947 10.1016/j.molcel.2014.03.003
54. Dondelinger Y Declercq W Montessuit S Roelandt R Goncalves A Bruggeman I MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates Cell Rep 2014 7 971 81 10.1016/j.celrep.2014.04.026 24813885
Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7:971–81.24813885 10.1016/j.celrep.2014.04.026
55. Zhang Y Su SS Zhao S Yang Z Zhong C Chen X RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome Nat Commun 2017 8 14329 10.1038/ncomms14329 28176780
Zhang Y, Su SS, Zhao S, Yang Z, Zhong C, Chen X, et al. RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome. Nat Commun. 2017;8:14329.28176780 10.1038/ncomms14329
56. Sun HJ Jiao B Wang Y Zhang YH Chen G Wang ZX Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions World J Gastroenterol 2024 30 1968 81 10.3748/wjg.v30.i14.1968 38681120
Sun HJ, Jiao B, Wang Y, Zhang YH, Chen G, Wang ZX, et al. Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions. World J Gastroenterol. 2024;30:1968–81.38681120 10.3748/wjg.v30.i14.1968
57. Preston SP Stutz MD Allison CC Nachbur U Gouil Q Tran BM Epigenetic silencing of RIPK3 in hepatocytes prevents MLKL-mediated necroptosis from contributing to liver pathologies Gastroenterology 2022 163 1643 57 10.1053/j.gastro.2022.08.040 36037995
Preston SP, Stutz MD, Allison CC, Nachbur U, Gouil Q, Tran BM, et al. Epigenetic silencing of RIPK3 in hepatocytes prevents MLKL-mediated necroptosis from contributing to liver pathologies. Gastroenterology. 2022;163:1643–57.36037995 10.1053/j.gastro.2022.08.040
58. Afonso MB Rodrigues PM Carvalho T Caridade M Borralho P Cortez-Pinto H Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis Clin Sci 2015 129 721 39 10.1042/CS20140732
Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H, et al. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci. 2015;129:721–39.10.1042/CS20140732
59. Gautheron J Vucur M Luedde T Necroptosis in nonalcoholic steatohepatitis Cell Mol Gastroenterol Hepatol 2015 1 264 5 10.1016/j.jcmgh.2015.02.001 28210679
Gautheron J, Vucur M, Luedde T. Necroptosis in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol. 2015;1:264–5.28210679 10.1016/j.jcmgh.2015.02.001
60. Saeed WK Jun DW Jang K Oh JH Chae YJ Lee JS Decrease in fat de novo synthesis and chemokine ligand expression in non‐alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain‐like pseudokinase J Gastroenterol Hepatol 2019 34 2206 18 10.1111/jgh.14740 31132314
Saeed WK, Jun DW, Jang K, Oh JH, Chae YJ, Lee JS, et al. Decrease in fat de novo synthesis and chemokine ligand expression in non‐alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain‐like pseudokinase. J Gastroenterol Hepatol. 2019;34:2206–18.31132314 10.1111/jgh.14740
61. Gautheron J Vucur M Reisinger F Cardenas DV Roderburg C Koppe C A positive feedback loop between RIP3 and JNK controls non‐alcoholic steatohepatitis EMBO Mol Med 2014 6 1062 74 10.15252/emmm.201403856 24963148
Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, et al. A positive feedback loop between RIP3 and JNK controls non‐alcoholic steatohepatitis. EMBO Mol Med. 2014;6:1062–74.24963148 10.15252/emmm.201403856
62. Kanazawa J Kakisaka K Suzuki Y Yonezawa T Abe H Wang T Excess fructose enhances oleatic cytotoxicity via reactive oxygen species production and causes necroptosis in hepatocytes J Nutr Biochem 2022 107 109052 10.1016/j.jnutbio.2022.109052 35609854
Kanazawa J, Kakisaka K, Suzuki Y, Yonezawa T, Abe H, Wang T, et al. Excess fructose enhances oleatic cytotoxicity via reactive oxygen species production and causes necroptosis in hepatocytes. J Nutr Biochem. 2022;107:109052.35609854 10.1016/j.jnutbio.2022.109052
63. Gautheron J Vucur M Schneider AT Severi I Roderburg C Roy S The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance Nat Commun 2016 7 11869 10.1038/ncomms11869 27323669
Gautheron J, Vucur M, Schneider AT, Severi I, Roderburg C, Roy S, et al. The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. Nat Commun. 2016;7:11869.27323669 10.1038/ncomms11869
64. Roychowdhury S McCullough RL Sanz-Garcia C Saikia P Alkhouri N Matloob A Receptor interacting protein 3 protects mice from high‐fat diet‐induced liver injury Hepatology 2016 64 1518 33 10.1002/hep.28676 27301788
Roychowdhury S, McCullough RL, Sanz-Garcia C, Saikia P, Alkhouri N, Matloob A, et al. Receptor interacting protein 3 protects mice from high‐fat diet‐induced liver injury. Hepatology. 2016;64:1518–33.27301788 10.1002/hep.28676
65. Tomita K Tamiya G Ando S Ohsumi K Chiyo T Mizutani A Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice Gut 2006 55 415 24 10.1136/gut.2005.071118 16174657
Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415–24.16174657 10.1136/gut.2005.071118
66. Ribeiro PS Cortez-Pinto H Solá S Castro RE Ramalho RM Baptista A Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients Am J Gastroenterol 2004 99 1708 17 10.1111/j.1572-0241.2004.40009.x 15330907
Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99:1708–17.15330907 10.1111/j.1572-0241.2004.40009.x
67. Roh YS Seki E Toll‐like receptors in alcoholic liver disease, non‐alcoholic steatohepatitis and carcinogenesis J Gastroenterol Hepatol 2013 28 38 42 10.1111/jgh.12019 23855294
Roh YS, Seki E. Toll‐like receptors in alcoholic liver disease, non‐alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol. 2013;28:38–42.23855294 10.1111/jgh.12019
68. Inaba Y Hashiuchi E Watanabe H Kimura K Oshima Y Tsuchiya K The transcription factor ATF3 switches cell death from apoptosis to necroptosis in hepatic steatosis in male mice Nat Commun 2023 14 167 10.1038/s41467-023-35804-w 36690638
Inaba Y, Hashiuchi E, Watanabe H, Kimura K, Oshima Y, Tsuchiya K, et al. The transcription factor ATF3 switches cell death from apoptosis to necroptosis in hepatic steatosis in male mice. Nat Commun. 2023;14:167.36690638 10.1038/s41467-023-35804-w
69. Zhang H Zhou L Zhou Y Wang L Jiang W Liu L Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway Life Sci 2021 285 119963 10.1016/j.lfs.2021.119963 34536498
Zhang H, Zhou L, Zhou Y, Wang L, Jiang W, Liu L, et al. Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway. Life Sci. 2021;285:119963.34536498 10.1016/j.lfs.2021.119963
70. Briand F Heymes C Bonada L Angles T Charpentier J Branchereau M A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death Clin Transl Sci 2020 13 529 38 10.1111/cts.12735 31981449
Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, et al. A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. Clin Transl Sci. 2020;13:529–38.31981449 10.1111/cts.12735
71. Majdi A Aoudjehane L Ratziu V Islam T Afonso MB Conti F Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease J Hepatol 2020 72 627 35 10.1016/j.jhep.2019.11.008 31760070
Majdi A, Aoudjehane L, Ratziu V, Islam T, Afonso MB, Conti F, et al. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020;72:627–35.31760070 10.1016/j.jhep.2019.11.008
72. Park J Rah SY An HS Lee JY Roh GS Ryter SW Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis Metabolism 2023 141 155516 10.1016/j.metabol.2023.155516 36773805
Park J, Rah SY, An HS, Lee JY, Roh GS, Ryter SW, et al. Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis. Metabolism. 2023;141:155516.36773805 10.1016/j.metabol.2023.155516
73. Ding HR Tang ZT Tang N Zhu ZY Liu HY Pan CY Protective properties of FOXO1 inhibition in a murine model of non-alcoholic fatty liver disease are associated with attenuation of ER stress and necroptosis Front Physiol 2020 11 177 10.3389/fphys.2020.00177 32218743
Ding HR, Tang ZT, Tang N, Zhu ZY, Liu HY, Pan CY, et al. Protective properties of FOXO1 inhibition in a murine model of non-alcoholic fatty liver disease are associated with attenuation of ER stress and necroptosis. Front Physiol. 2020;11:177.32218743 10.3389/fphys.2020.00177
74. Zychlinsky A Prevost MC Sansonetti PJ Shigella flexneri induces apoptosis in infected macrophages Nature 1992 358 167 9 10.1038/358167a0 1614548
Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature. 1992;358:167–9.1614548 10.1038/358167a0
75. de Vasconcelos NM Van Opdenbosch N Van Gorp H Parthoens E Lamkanfi M Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture Cell Death Differ 2018 26 146 61 10.1038/s41418-018-0106-7 29666477
de Vasconcelos NM, Van Opdenbosch N, Van Gorp H, Parthoens E, Lamkanfi M. Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. Cell Death Differ. 2018;26:146–61.29666477 10.1038/s41418-018-0106-7
76. Lamkanfi M Dixit VM Mechanisms and functions of inflammasomes Cell 2014 157 1013 22 10.1016/j.cell.2014.04.007 24855941
Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013–22.24855941 10.1016/j.cell.2014.04.007
77. Schroder K Tschopp J The Inflammasomes Cell 2010 140 821 32 10.1016/j.cell.2010.01.040 20303873
Schroder K, Tschopp J. The Inflammasomes. Cell. 2010;140:821–32.20303873 10.1016/j.cell.2010.01.040
78. Broz P Dixit VM Inflammasomes: mechanism of assembly, regulation and signalling Nat Rev Immunol 2016 16 407 20 10.1038/nri.2016.58 27291964
Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407–20.27291964 10.1038/nri.2016.58
79. Kesavardhana S Malireddi RKS Kanneganti TD Caspases in cell death, inflammation, and pyroptosis Annu Rev Immunol 2020 38 567 95 10.1146/annurev-immunol-073119-095439 32017655
Kesavardhana S, Malireddi RKS, Kanneganti TD. Caspases in cell death, inflammation, and pyroptosis. Annu Rev Immunol. 2020;38:567–95.32017655 10.1146/annurev-immunol-073119-095439
80. Broz P Pelegrín P Shao F The gasdermins, a protein family executing cell death and inflammation Nat Rev Immunol 2020 20 143 57 10.1038/s41577-019-0228-2 31690840
Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20:143–57.31690840 10.1038/s41577-019-0228-2
81. Shi J Zhao Y Wang K Shi X Wang Y Huang H Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death Nature 2015 526 660 5 10.1038/nature15514 26375003
Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660–5.26375003 10.1038/nature15514
82. Mitsuyoshi H Yasui K Hara T Taketani H Ishiba H Okajima A Hepatic nucleotide binding oligomerization domain‐like receptors pyrin domain‐containing 3 inflammasomes are associated with the histologic severity of non‐alcoholic fatty liver disease Hepatol Res 2017 47 1459 68 10.1111/hepr.12883 28245087
Mitsuyoshi H, Yasui K, Hara T, Taketani H, Ishiba H, Okajima A, et al. Hepatic nucleotide binding oligomerization domain‐like receptors pyrin domain‐containing 3 inflammasomes are associated with the histologic severity of non‐alcoholic fatty liver disease. Hepatol Res. 2017;47:1459–68.28245087 10.1111/hepr.12883
83. Dixon LJ Flask CA Papouchado BG Feldstein AE Nagy LE Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis PLoS ONE 2013 8 e56100 10.1371/journal.pone.0056100 23409132
Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS ONE. 2013;8:e56100.23409132 10.1371/journal.pone.0056100
84. Dixon LJ Berk M Thapaliya S Papouchado BG Feldstein AE Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis Lab Investig 2012 92 713 23 10.1038/labinvest.2012.45 22411067
Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Investig. 2012;92:713–23.22411067 10.1038/labinvest.2012.45
85. Mirea AM Stienstra R Kanneganti TD Tack CJ Chavakis T Toonen EJM Mice deficient in the IL-1β activation genes Prtn3, Elane, and Casp1 are protected against the development of obesity-induced NAFLD Inflammation 2020 43 1054 64 10.1007/s10753-020-01190-4 32002713
Mirea AM, Stienstra R, Kanneganti TD, Tack CJ, Chavakis T, Toonen EJM, et al. Mice deficient in the IL-1β activation genes Prtn3, Elane, and Casp1 are protected against the development of obesity-induced NAFLD. Inflammation. 2020;43:1054–64.32002713 10.1007/s10753-020-01190-4
86. Xu B Jiang M Chu Y Wang W Chen D Li X Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice J Hepatol 2018 68 773 82 10.1016/j.jhep.2017.11.040 29273476
Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol. 2018;68:773–82.29273476 10.1016/j.jhep.2017.11.040
87. Wree A McGeough MD Peña CA Schlattjan M Li H Inzaugarat ME NLRP3 inflammasome activation is required for fibrosis development in NAFLD J Mol Med 2014 92 1069 82 10.1007/s00109-014-1170-1 24861026
Wree A, McGeough MD, Peña CA, Schlattjan M, Li H, Inzaugarat ME, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med. 2014;92:1069–82.24861026 10.1007/s00109-014-1170-1
88. Wree A Eguchi A McGeough MD Pena CA Johnson CD Canbay A NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice Hepatology 2014 59 898 910 10.1002/hep.26592 23813842
Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898–910.23813842 10.1002/hep.26592
89. Yu L Hong W Lu S Li Y Guan Y Weng X The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment Front Pharmacol 2022 13 780496 10.3389/fphar.2022.780496 35350750
Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment. Front Pharmacol. 2022;13:780496.35350750 10.3389/fphar.2022.780496
90. Csak T Ganz M Pespisa J Kodys K Dolganiuc A Szabo G Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells Hepatology 2011 54 133 44 10.1002/hep.24341 21488066
Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54:133–44.21488066 10.1002/hep.24341
91. Pan J Ou Z Cai C Li P Gong J Ruan XZ Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release Cell Immunol 2018 332 111 20 10.1016/j.cellimm.2018.08.006 30103942
Pan J, Ou Z, Cai C, Li P, Gong J, Ruan XZ, et al. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release. Cell Immunol. 2018;332:111–20.30103942 10.1016/j.cellimm.2018.08.006
92. Xu L Zhou J Che J Wang H Yang W Zhou W Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease Am J Physiol Gastrointest Liver Physiol 2021 320 G1034 G1044 10.1152/ajpgi.00431.2020 33728991
Xu L, Zhou J, Che J, Wang H, Yang W, Zhou W, et al. Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2021;320:G1034–G1044.33728991 10.1152/ajpgi.00431.2020
93. Chen Y Ma K NLRC4 inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease Biochem Biophys Res Commun 2019 511 524 30 10.1016/j.bbrc.2019.02.099 30824190
Chen Y, Ma K. NLRC4 inflammasome activation regulated by TNF-α promotes inflammatory responses in nonalcoholic fatty liver disease. Biochem Biophys Res Commun. 2019;511:524–30.30824190 10.1016/j.bbrc.2019.02.099
94. Drummer C 4th Saaoud F Jhala NC Cueto R Sun Y Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages Front Immunol 2023 14 1113883 10.3389/fimmu.2023.1113883 36776889
Drummer C 4th, Saaoud F, Jhala NC, Cueto R, Sun Y, et al. Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages. Front Immunol. 2023;14:1113883.36776889 10.3389/fimmu.2023.1113883
95. Zhu Y Zhao H Lu J Lin K Ni J Wu G Caspase-11–mediated hepatocytic pyroptosis promotes the progression of nonalcoholic steatohepatitis Cell Mol Gastroenterol Hepatol 2021 12 653 64 10.1016/j.jcmgh.2021.04.009 33894425
Zhu Y, Zhao H, Lu J, Lin K, Ni J, Wu G, et al. Caspase-11–mediated hepatocytic pyroptosis promotes the progression of nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol. 2021;12:653–64.33894425 10.1016/j.jcmgh.2021.04.009
96. Liu Y Wang DW Wang D Duan BH Kuang HY Exenatide attenuates non-alcoholic steatohepatitis by inhibiting the pyroptosis signaling pathway Front Endocrinol 2021 12 663039 10.3389/fendo.2021.663039
Liu Y, Wang DW, Wang D, Duan BH, Kuang HY. Exenatide attenuates non-alcoholic steatohepatitis by inhibiting the pyroptosis signaling pathway. Front Endocrinol. 2021;12:663039.10.3389/fendo.2021.663039
97. Hao YY Cui WW Gao HL Wang MY Liu Y Li CR Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis Pharm Biol 2022 60 274 81 10.1080/13880209.2022.2029501 35138995
Hao YY, Cui WW, Gao HL, Wang MY, Liu Y, Li CR, et al. Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis. Pharm Biol. 2022;60:274–81.35138995 10.1080/13880209.2022.2029501
98. Ruan S Han C Sheng Y Wang J Zhou X Guan Q Antcin A alleviates pyroptosis and inflammatory response in Kupffer cells of non-alcoholic fatty liver disease by targeting NLRP3 Int Immunopharmacol 2021 100 108126 10.1016/j.intimp.2021.108126 34492534
Ruan S, Han C, Sheng Y, Wang J, Zhou X, Guan Q, et al. Antcin A alleviates pyroptosis and inflammatory response in Kupffer cells of non-alcoholic fatty liver disease by targeting NLRP3. Int Immunopharmacol. 2021;100:108126.34492534 10.1016/j.intimp.2021.108126
99. Oh S Son M Byun KA Jang JT Choi CH Son KH Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis Mar Drugs 2021 19 318 10.3390/md19060318 34070893
Oh S, Son M, Byun KA, Jang JT, Choi CH, Son KH, et al. Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis. Mar Drugs. 2021;19:318.34070893 10.3390/md19060318
100. Mridha AR Wree A Robertson AAB Yeh MM Johnson CD Van Rooyen DM NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice J Hepatol 2017 66 1037 46 10.1016/j.jhep.2017.01.022 28167322
Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66:1037–46.28167322 10.1016/j.jhep.2017.01.022
101. Zhang X Shang X Jin S Ma Z Wang H Ao N Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats Arch Biochem Biophys 2021 705 108894 10.1016/j.abb.2021.108894 33965368
Zhang X, Shang X, Jin S, Ma Z, Wang H, Ao N, et al. Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats. Arch Biochem Biophys. 2021;705:108894.33965368 10.1016/j.abb.2021.108894
102. Yong Z Ruiqi W Hongji Y Ning M Chenzuo J Yu Z Mangiferin ameliorates HFD-induced NAFLD through regulation of the AMPK and NLRP3 inflammasome signal pathways J Immunol Res 2021 2021 4084566 10.1155/2021/4084566 34734090
Yong Z, Ruiqi W, Hongji Y, Ning M, Chenzuo J, Yu Z, et al. Mangiferin ameliorates HFD-induced NAFLD through regulation of the AMPK and NLRP3 inflammasome signal pathways. J Immunol Res. 2021;2021:4084566.34734090 10.1155/2021/4084566
103. Qiu T Pei P Yao X Jiang L Wei S Wang Z Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway Cell Death Dis 2018 9 946 10.1038/s41419-018-1004-0 30237538
Qiu T, Pei P, Yao X, Jiang L, Wei S, Wang Z, et al. Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway. Cell Death Dis. 2018;9:946.30237538 10.1038/s41419-018-1004-0
104. Shen T Lei T Chen L Zhu BB Xu BL Zhang CP Gardenoside hinders caspase-1-mediated hepatocyte pyroptosis through the CTCF/DPP4 signaling pathway Front Physiol 2021 12 669202 10.3389/fphys.2021.669202 34566670
Shen T, Lei T, Chen L, Zhu BB, Xu BL, Zhang CP, et al. Gardenoside hinders caspase-1-mediated hepatocyte pyroptosis through the CTCF/DPP4 signaling pathway. Front Physiol. 2021;12:669202.34566670 10.3389/fphys.2021.669202
105. Zhong H Liu M Ji Y Ma M Chen K Liang T Genipin reverses HFD-induced liver damage and inhibits UCP2-mediated pyroptosis in mice Cell Physiol Biochem 2018 49 1885 97 10.1159/000493651 30235442
Zhong H, Liu M, Ji Y, Ma M, Chen K, Liang T, et al. Genipin reverses HFD-induced liver damage and inhibits UCP2-mediated pyroptosis in mice. Cell Physiol Biochem. 2018;49:1885–97.30235442 10.1159/000493651
106. Chen T Meng Y Zhou Z Li H Wan L Kang A GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis Cell Death Differ 2023 30 1829 48 10.1038/s41418-023-01183-4 37337032
Chen T, Meng Y, Zhou Z, Li H, Wan L, Kang A, et al. GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis. Cell Death Differ. 2023;30:1829–48.37337032 10.1038/s41418-023-01183-4
107. Jiang X Li Y Fu D You T Wu S Xin J Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway Int Immunopharmacol 2023 114 109558 10.1016/j.intimp.2022.109558 36700765
Jiang X, Li Y, Fu D, You T, Wu S, Xin J, et al. Caveolin-1 ameliorates acetaminophen-aggravated inflammatory damage and lipid deposition in non-alcoholic fatty liver disease via the ROS/TXNIP/NLRP3 pathway. Int Immunopharmacol. 2023;114:109558.36700765 10.1016/j.intimp.2022.109558
108. Mai W Xu Y Xu J Zhao D Ye L Yu G Berberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS/TXNIP axis Front Pharmacol 2020 11 185 10.3389/fphar.2020.00185 32194416
Mai W, Xu Y, Xu J, Zhao D, Ye L, Yu G, et al. Berberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS/TXNIP axis. Front Pharmacol. 2020;11:185.32194416 10.3389/fphar.2020.00185
109. Ding C Zhao Y Shi X Zhang N Zu G Li Z New insights into salvianolic acid A action: regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats Sci Rep 2016 6 28734 10.1038/srep28734 27345365
Ding C, Zhao Y, Shi X, Zhang N, Zu G, Li Z, et al. New insights into salvianolic acid A action: regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Sci Rep. 2016;6:28734.27345365 10.1038/srep28734
110. Yu X Hao M Liu Y Ma X Lin W Xu Q Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy Eur J Pharmacol 2019 864 172715 10.1016/j.ejphar.2019.172715 31593687
Yu X, Hao M, Liu Y, Ma X, Lin W, Xu Q, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol. 2019;864:172715.31593687 10.1016/j.ejphar.2019.172715
111. Shi H Zhang Y Xing J Liu L Qiao F Li J Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis Int Immunopharmacol 2020 81 106195 10.1016/j.intimp.2020.106195 32028242
Shi H, Zhang Y, Xing J, Liu L, Qiao F, Li J, et al. Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis. Int Immunopharmacol. 2020;81:106195.32028242 10.1016/j.intimp.2020.106195
112. Shi H Qiao F Lu W Huang K Wen Y Ye L Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway Eur J Pharmacol 2022 934 175270 10.1016/j.ejphar.2022.175270 36184988
Shi H, Qiao F, Lu W, Huang K, Wen Y, Ye L, et al. Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway. Eur J Pharmacol. 2022;934:175270.36184988 10.1016/j.ejphar.2022.175270
113. Biao Y Chen J Liu C Wang R Han X Li L Protective effect of Danshen zexie decoction against non-alcoholic fatty liver disease through inhibition of ROS/NLRP3/IL-1β pathway by Nrf2 signaling activation Front Pharmacol 2022 13 877924 10.3389/fphar.2022.877924 35800450
Biao Y, Chen J, Liu C, Wang R, Han X, Li L, et al. Protective effect of Danshen zexie decoction against non-alcoholic fatty liver disease through inhibition of ROS/NLRP3/IL-1β pathway by Nrf2 signaling activation. Front Pharmacol. 2022;13:877924.35800450 10.3389/fphar.2022.877924
114. Yin K Zhou X Jiang W Wang L Dai Z Tang B Jiangzhi Ligan Decoction inhibits GSDMD-mediated canonical/noncanonical pyroptosis pathways and alleviates high-fat diet-induced nonalcoholic fatty liver disease Dis Markers 2021 2021 9963534 10.1155/2021/9963534 34239622
Yin K, Zhou X, Jiang W, Wang L, Dai Z, Tang B. Jiangzhi Ligan Decoction inhibits GSDMD-mediated canonical/noncanonical pyroptosis pathways and alleviates high-fat diet-induced nonalcoholic fatty liver disease. Dis Markers. 2021;2021:9963534.34239622 10.1155/2021/9963534
115. Dixon SJ Lemberg KM Lamprecht MR Skouta R Zaitsev EM Gleason CE Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 72 10.1016/j.cell.2012.03.042 22632970
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.22632970 10.1016/j.cell.2012.03.042
116. Lo M Wang YZ Gout PW The xc− cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases J Cell Physiol 2008 215 593 602 10.1002/jcp.21366 18181196
Lo M, Wang YZ, Gout PW. The xc − cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215:593–602.18181196 10.1002/jcp.21366
117. Yang WS SriRamaratnam R Welsch ME Shimada K Skouta R Viswanathan VS Regulation of ferroptotic cancer cell death by GPX4 Cell 2014 156 317 31 10.1016/j.cell.2013.12.010 24439385
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.24439385 10.1016/j.cell.2013.12.010
118. Conrad M Pratt DA The chemical basis of ferroptosis Nat Chem Biol 2019 15 1137 47 10.1038/s41589-019-0408-1 31740834
Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15:1137–47.31740834 10.1038/s41589-019-0408-1
119. Sun X Ou Z Chen R Niu X Chen D Kang R Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells Hepatology 2016 63 173 84 10.1002/hep.28251 26403645
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63:173–84.26403645 10.1002/hep.28251
120. Gout PW Buckley AR Simms CR Bruchovsky N Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug Leukemia 2001 15 1633 40 10.1038/sj.leu.2402238 11587223
Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633–40.11587223 10.1038/sj.leu.2402238
121. Friedmann Angeli JP Schneider M Proneth B Tyurina YY Tyurin VA Hammond VJ Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice Nat Cell Biol 2014 16 1180 91 10.1038/ncb3064 25402683
Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180–91.25402683 10.1038/ncb3064
122. Jiang L Kon N Li T Wang SJ Su T Hibshoosh H Ferroptosis as a p53-mediated activity during tumour suppression Nature 2015 520 57 62 10.1038/nature14344 25799988
Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57–62.25799988 10.1038/nature14344
123. Doll S Freitas FP Shah R Aldrovandi M da Silva MC Ingold I FSP1 is a glutathione-independent ferroptosis suppressor Nature 2019 575 693 8 10.1038/s41586-019-1707-0 31634899
Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693–8.31634899 10.1038/s41586-019-1707-0
124. Wang S Liu Z Geng J Li L Feng X An overview of ferroptosis in non-alcoholic fatty liver disease Biomed Pharmacother 2022 153 113374 10.1016/j.biopha.2022.113374 35834990
Wang S, Liu Z, Geng J, Li L, Feng X. An overview of ferroptosis in non-alcoholic fatty liver disease. Biomed Pharmacother. 2022;153:113374.35834990 10.1016/j.biopha.2022.113374
125. Kraft VAN Bezjian CT Pfeiffer S Ringelstetter L Müller C Zandkarimi F GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling ACS Cent Sci 2020 6 41 53 10.1021/acscentsci.9b01063 31989025
Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Müller C, Zandkarimi F, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020;6:41–53.31989025 10.1021/acscentsci.9b01063
126. Videla LA Valenzuela R Perspectives in liver redox imbalance: toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action BioFactors 2021 48 400 15 10.1002/biof.1797 34687092
Videla LA, Valenzuela R. Perspectives in liver redox imbalance: toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. BioFactors. 2021;48:400–15.34687092 10.1002/biof.1797
127. Folgueras AR Freitas-Rodríguez S Ramsay AJ Garabaya C Rodríguez F Velasco G Matriptase-2 deficiency protects from obesity by modulating iron homeostasis Nat Commun 2018 9 1350 10.1038/s41467-018-03853-1 29636509
Folgueras AR, Freitas-Rodríguez S, Ramsay AJ, Garabaya C, Rodríguez F, Velasco G, et al. Matriptase-2 deficiency protects from obesity by modulating iron homeostasis. Nat Commun. 2018;9:1350.29636509 10.1038/s41467-018-03853-1
128. Rametta R Fracanzani AL Fargion S Dongiovanni P Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (DIOS): two related conditions or different entities? Curr Pharm Des 2020 26 1025 35 10.2174/1381612826666200131103018 32003680
Rametta R, Fracanzani AL, Fargion S, Dongiovanni P. Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (DIOS): two related conditions or different entities? Curr Pharm Des. 2020;26:1025–35.32003680 10.2174/1381612826666200131103018
129. Kowdley KV Belt P Wilson LA Yeh MM Neuschwander-Tetri BA Chalasani N Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease Hepatology 2012 55 77 85 10.1002/hep.24706 21953442
Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77–85.21953442 10.1002/hep.24706
130. Meli R Mattace Raso G Irace C Simeoli R Di Pascale A Paciello O High fat diet induces liver steatosis and early dysregulation of iron metabolism in rats PLoS ONE 2013 8 e66570 10.1371/journal.pone.0066570 23805238
Meli R, Mattace Raso G, Irace C, Simeoli R, Di Pascale A, Paciello O, et al. High fat diet induces liver steatosis and early dysregulation of iron metabolism in rats. PLoS ONE. 2013;8:e66570.23805238 10.1371/journal.pone.0066570
131. Chen J Li X Ge C Min J Wang F The multifaceted role of ferroptosis in liver disease Cell Death Differ 2022 29 467 80 10.1038/s41418-022-00941-0 35075250
Chen J, Li X, Ge C, Min J, Wang F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ. 2022;29:467–80.35075250 10.1038/s41418-022-00941-0
132. Loguercio C De Girolamo V de Sio I Tuccillo C Ascione A Baldi F Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects J Hepatol 2001 35 568 74 10.1016/S0168-8278(01)00192-1 11690701
Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol. 2001;35:568–74.11690701 10.1016/S0168-8278(01)00192-1
133. Qi J Kim JW Zhou Z Lim CW Kim B Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation–mediated cell death in mice Am J Pathol 2020 190 68 81 10.1016/j.ajpath.2019.09.011 31610178
Qi J, Kim JW, Zhou Z, Lim CW, Kim B. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation–mediated cell death in mice. Am J Pathol. 2020;190:68–81.31610178 10.1016/j.ajpath.2019.09.011
134. Wei S Qiu T Wang N Yao X Jiang L Jia X Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis Environ Res 2020 188 109824 10.1016/j.envres.2020.109824 32593899
Wei S, Qiu T, Wang N, Yao X, Jiang L, Jia X, et al. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis. Environ Res. 2020;188:109824.32593899 10.1016/j.envres.2020.109824
135. Tsurusaki S Tsuchiya Y Koumura T Nakasone M Sakamoto T Matsuoka M Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis Cell Death Dis 2019 10 449 10.1038/s41419-019-1678-y 31209199
Tsurusaki S, Tsuchiya Y, Koumura T, Nakasone M, Sakamoto T, Matsuoka M, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis. 2019;10:449.31209199 10.1038/s41419-019-1678-y
136. Xie Y Hou W Song X Yu Y Huang J Sun X Ferroptosis: process and function Cell Death Differ 2016 23 369 79 10.1038/cdd.2015.158 26794443
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369–79.26794443 10.1038/cdd.2015.158
137. Li X Wang TX Huang X Li Y Sun T Zang S Targeting ferroptosis alleviates methionine‐choline deficient (MCD)‐diet induced NASH by suppressing liver lipotoxicity Liver Int 2020 40 1378 94 10.1111/liv.14428 32145145
Li X, Wang TX, Huang X, Li Y, Sun T, Zang S, et al. Targeting ferroptosis alleviates methionine‐choline deficient (MCD)‐diet induced NASH by suppressing liver lipotoxicity. Liver Int. 2020;40:1378–94.32145145 10.1111/liv.14428
138. Zhang J Xie H Yao J Jin W Pan H Pan Z TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination Hum Cell 2023 36 209 22 10.1007/s13577-022-00820-3 36417114
Zhang J, Xie H, Yao J, Jin W, Pan H, Pan Z, et al. TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination. Hum Cell. 2023;36:209–22.36417114 10.1007/s13577-022-00820-3
139. Yu L He M Liu S Dou X Li L Gu N Fluorescent egg white-based carbon dots as a high-sensitivity iron chelator for the therapy of nonalcoholic fatty liver disease by iron overload in zebrafish ACS Appl Mater Interfaces 2021 13 54677 89 10.1021/acsami.1c14674 34756030
Yu L, He M, Liu S, Dou X, Li L, Gu N, et al. Fluorescent egg white-based carbon dots as a high-sensitivity iron chelator for the therapy of nonalcoholic fatty liver disease by iron overload in zebrafish. ACS Appl Mater Interfaces. 2021;13:54677–89.34756030 10.1021/acsami.1c14674
140. Wang Y Bo J Zhao Z Han Y Zhang Q Liu L Depletion of Igfbp7 alleviates zebrafish NAFLD progression through inhibiting hepatic ferroptosis Life Sci 2023 332 122086 10.1016/j.lfs.2023.122086 37714372
Wang Y, Bo J, Zhao Z, Han Y, Zhang Q, Liu L. Depletion of Igfbp7 alleviates zebrafish NAFLD progression through inhibiting hepatic ferroptosis. Life Sci. 2023;332:122086.37714372 10.1016/j.lfs.2023.122086
141. Park JB Ko K Baek YH Kwon WY Suh S Han SH Pharmacological prevention of ectopic erythrophagocytosis by cilostazol mitigates ferroptosis in NASH Int J Mol Sci 2023 24 12862 10.3390/ijms241612862 37629045
Park JB, Ko K, Baek YH, Kwon WY, Suh S, Han SH, et al. Pharmacological prevention of ectopic erythrophagocytosis by cilostazol mitigates ferroptosis in NASH. Int J Mol Sci. 2023;24:12862.37629045 10.3390/ijms241612862
142. Jiang T Xiao Y Zhou J Luo Z Yu L Liao Q Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway Redox Biol 2023 68 102963 10.1016/j.redox.2023.102963 37984229
Jiang T, Xiao Y, Zhou J, Luo Z, Yu L, Liao Q, et al. Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway. Redox Biol. 2023;68:102963.37984229 10.1016/j.redox.2023.102963
143. Choi J Choi H Chung J Icariin supplementation suppresses the markers of ferroptosis and attenuates the progression of nonalcoholic steatohepatitis in mice fed a methionine choline-deficient diet Int J Mol Sci 2023 24 12510 10.3390/ijms241512510 37569885
Choi J, Choi H, Chung J. Icariin supplementation suppresses the markers of ferroptosis and attenuates the progression of nonalcoholic steatohepatitis in mice fed a methionine choline-deficient diet. Int J Mol Sci. 2023;24:12510.37569885 10.3390/ijms241512510
144. He F Zhang P Liu J Wang R Kaufman RJ Yaden BC ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis J Hepatol 2023 79 362 77 10.1016/j.jhep.2023.03.016 36996941
He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023;79:362–77.36996941 10.1016/j.jhep.2023.03.016
145. Yang M Xia L Song J Hu H Zang N Yang J Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation Lipids Health Dis 2023 22 202 10.1186/s12944-023-01969-y 38001459
Yang M, Xia L, Song J, Hu H, Zang N, Yang J, et al. Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation. Lipids Health Dis. 2023;22:202.38001459 10.1186/s12944-023-01969-y
146. Yuan X Li L Zhang Y Ai R Li D Dou Y Heme oxygenase 1 alleviates nonalcoholic steatohepatitis by suppressing hepatic ferroptosis Lipids Health Dis 2023 22 99 10.1186/s12944-023-01855-7 37422643
Yuan X, Li L, Zhang Y, Ai R, Li D, Dou Y, et al. Heme oxygenase 1 alleviates nonalcoholic steatohepatitis by suppressing hepatic ferroptosis. Lipids Health Dis. 2023;22:99.37422643 10.1186/s12944-023-01855-7
147. Saha M Das S Manna K Saha KD Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model Biosci Rep 2023 43 BSR20230128 10.1042/BSR20230128 37728565
Saha M, Das S, Manna K, Saha KD. Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model. Biosci Rep. 2023;43:BSR20230128.37728565 10.1042/BSR20230128
148. Gao G Xie Z Li EW Yuan Y Fu Y Wang P Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis J Nat Med 2021 75 540 52 10.1007/s11418-021-01491-4 33590347
Gao G, Xie Z, Li EW, Yuan Y, Fu Y, Wang P, et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis. J Nat Med. 2021;75:540–52.33590347 10.1007/s11418-021-01491-4
149. Yang Y Chen J Gao Q Shan X Wang J Lv Z Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease Toxicology 2020 445 152599 10.1016/j.tox.2020.152599 32976958
Yang Y, Chen J, Gao Q, Shan X, Wang J, Lv Z. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology. 2020;445:152599.32976958 10.1016/j.tox.2020.152599
150. Liu B Yi W Mao X Yang L Rao C Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis Am J Physiol Endocrinol Metab 2021 320 E925 E937 10.1152/ajpendo.00614.2020 33813878
Liu B, Yi W, Mao X, Yang L, Rao C. Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis. Am J Physiol Endocrinol Metab. 2021;320:E925–E937.33813878 10.1152/ajpendo.00614.2020
151. Xing G Meng L Cao S Liu S Wu J Li Q PPARα alleviates iron overload‐induced ferroptosis in mouse liver EMBO Rep 2022 23 e52280 10.15252/embr.202052280 35703725
Xing G, Meng L, Cao S, Liu S, Wu J, Li Q, et al. PPARα alleviates iron overload‐induced ferroptosis in mouse liver. EMBO Rep. 2022;23:e52280.35703725 10.15252/embr.202052280
152. Shu YY Gao WK Chu HK Yang L Pan XL Ye J Attenuation by time-restricted feeding of high-fat and high-fructose diet-induced NASH in mice is related to Per2 and ferroptosis Oxid Med Cell Longev 2022 2022 8063897 10.1155/2022/8063897 36285301
Shu YY, Gao WK, Chu HK, Yang L, Pan XL, Ye J. Attenuation by time-restricted feeding of high-fat and high-fructose diet-induced NASH in mice is related to Per2 and ferroptosis. Oxid Med Cell Longev. 2022;2022:8063897.36285301 10.1155/2022/8063897
153. Zhu Z Zhang Y Huang X Can L Zhao X Wang Y Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4 Eur J Pharmacol 2021 908 174351 10.1016/j.ejphar.2021.174351 34280397
Zhu Z, Zhang Y, Huang X, Can L, Zhao X, Wang Y, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4. Eur J Pharmacol. 2021;908:174351.34280397 10.1016/j.ejphar.2021.174351
154. Wang X Ma B Wen X You H Sheng C Bu L Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis Cell Death Discov 2022 8 234 10.1038/s41420-022-01011-7 35477568
Wang X, Ma B, Wen X, You H, Sheng C, Bu L, et al. Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis. Cell Death Discov. 2022;8:234.35477568 10.1038/s41420-022-01011-7
155. Jiang JJ Zhang GF Zheng JY Sun JH Ding SB Targeting Mitochondrial ROS-Mediated Ferroptosis by Quercetin Alleviates High-Fat Diet-Induced Hepatic Lipotoxicity Front Pharmacol 2022 13 876550 10.3389/fphar.2022.876550 35496312
Jiang JJ, Zhang GF, Zheng JY, Sun JH, Ding SB. Targeting Mitochondrial ROS-Mediated Ferroptosis by Quercetin Alleviates High-Fat Diet-Induced Hepatic Lipotoxicity. Front Pharmacol. 2022;13:876550.35496312 10.3389/fphar.2022.876550
156. Jiang Z Sun H Miao J Sheng Q Xu J Gao Z The natural flavone acacetin protects against high-fat diet-induced lipid accumulation in the liver via the endoplasmic reticulum stress/ferroptosis pathway Biochem Biophys Res Commun 2023 640 183 91 10.1016/j.bbrc.2022.12.014 36516527
Jiang Z, Sun H, Miao J, Sheng Q, Xu J, Gao Z, et al. The natural flavone acacetin protects against high-fat diet-induced lipid accumulation in the liver via the endoplasmic reticulum stress/ferroptosis pathway. Biochem Biophys Res Commun. 2023;640:183–91.36516527 10.1016/j.bbrc.2022.12.014
157. Guo T Yan W Cui X Liu N Wei X Sun Y Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis Mol Med 2023 29 132 10.1186/s10020-023-00721-7 37770820
Guo T, Yan W, Cui X, Liu N, Wei X, Sun Y, et al. Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Mol Med. 2023;29:132.37770820 10.1186/s10020-023-00721-7
158. Zhao M Jin Z Xia C Chen S Zeng L Qin S Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery Biomaterials 2023 301 122230 10.1016/j.biomaterials.2023.122230 37418855
Zhao M, Jin Z, Xia C, Chen S, Zeng L, Qin S, et al. Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery. Biomaterials. 2023;301:122230.37418855 10.1016/j.biomaterials.2023.122230
159. Gaul S Leszczynska A Alegre F Kaufmann B Johnson CD Adams LA Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis J Hepatol 2021 74 156 67 10.1016/j.jhep.2020.07.041 32763266
Gaul S, Leszczynska A, Alegre F, Kaufmann B, Johnson CD, Adams LA, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol. 2021;74:156–67.32763266 10.1016/j.jhep.2020.07.041
160. Wiering L Subramanian P Hammerich L Hepatic stellate cells: dictating outcome in nonalcoholic fatty liver disease Cell Mol Gastroenterol Hepatol 2023 15 1277 92 10.1016/j.jcmgh.2023.02.010 36828280
Wiering L, Subramanian P, Hammerich L. Hepatic stellate cells: dictating outcome in nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 2023;15:1277–92.36828280 10.1016/j.jcmgh.2023.02.010
161. Kanda T Matsuoka S Yamazaki M Shibata T Nirei K Takahashi H Apoptosis and non-alcoholic fatty liver diseases World J Gastroenterol 2018 24 2661 72 10.3748/wjg.v24.i25.2661 29991872
Kanda T, Matsuoka S, Yamazaki M, Shibata T, Nirei K, Takahashi H, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol. 2018;24:2661–72.29991872 10.3748/wjg.v24.i25.2661
162. Guo R Jia X Ding Z Wang G Jiang M Li B Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation Theranostics 2022 12 5220 36 10.7150/thno.71400 35836819
Guo R, Jia X, Ding Z, Wang G, Jiang M, Li B, et al. Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation. Theranostics. 2022;12:5220–36.35836819 10.7150/thno.71400
163. Cho SS Yang JH Lee JH Baek JS Ku SK Cho IJ Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis Free Radic Biol Med 2022 193 620 37 10.1016/j.freeradbiomed.2022.11.011 36370962
Cho SS, Yang JH, Lee JH, Baek JS, Ku SK, Cho IJ, et al. Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis. Free Radic Biol Med. 2022;193:620–37.36370962 10.1016/j.freeradbiomed.2022.11.011
164. Zhang Z Guo M Li Y Shen M Kong D Shao J RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells Autophagy 2020 16 1482 505 10.1080/15548627.2019.1687985 31679460
Zhang Z, Guo M, Li Y, Shen M, Kong D, Shao J, et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy. 2020;16:1482–505.31679460 10.1080/15548627.2019.1687985
165. Zhang Z Yao Z Wang L Ding H Shao J Chen A Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells Autophagy 2018 14 2083 103 10.1080/15548627.2018.1503146 30081711
Zhang Z, Yao Z, Wang L, Ding H, Shao J, Chen A, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy. 2018;14:2083–103.30081711 10.1080/15548627.2018.1503146
166. Ni K Meng L Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease Clin Res Hepatol Gastroenterol 2024 48 102381 10.1016/j.clinre.2024.102381 38821484
Ni K, Meng L. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease. Clin Res Hepatol Gastroenterol. 2024;48:102381.38821484 10.1016/j.clinre.2024.102381
167. Ma Z Xie K Xue X Li J Yang Y Wu J Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA J Ethnopharmacol 2024 328 118057 10.1016/j.jep.2024.118057 38518965
Ma Z, Xie K, Xue X, Li J, Yang Y, Wu J, et al. Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA. J Ethnopharmacol. 2024;328:118057.38518965 10.1016/j.jep.2024.118057
168. Lee S Karki R Wang Y Nguyen LN Kalathur RC Kanneganti TD AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence Nature 2021 597 415 9 10.1038/s41586-021-03875-8 34471287
Lee S, Karki R, Wang Y, Nguyen LN, Kalathur RC, Kanneganti TD. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597:415–9.34471287 10.1038/s41586-021-03875-8
169. Taabazuing CY Okondo MC Bachovchin DA Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages Cell Chem Biol 2017 24 507 14.e4 10.1016/j.chembiol.2017.03.009 28392147
Taabazuing CY, Okondo MC, Bachovchin DA. Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages. Cell Chem Biol. 2017;24:507–14.e4.28392147 10.1016/j.chembiol.2017.03.009
170. Ezquerro S Mocha F Frühbeck G Guzmán-Ruiz R Valentí V Mugueta C Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD J Clin Endocrinol Metab 2019 104 21 37 30137403
Ezquerro S, Mocha F, Frühbeck G, Guzmán-Ruiz R, Valentí V, Mugueta C, et al. Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J Clin Endocrinol Metab. 2019;104:21–37.30137403
171. Liu M Lu J Hu J Chen Y Deng X Wang J Sodium sulfite triggered hepatic apoptosis, necroptosis, and pyroptosis by inducing mitochondrial damage in mice and AML-12 cells J Hazard Mater 2024 467 133719 10.1016/j.jhazmat.2024.133719 38335615
Liu M, Lu J, Hu J, Chen Y, Deng X, Wang J, et al. Sodium sulfite triggered hepatic apoptosis, necroptosis, and pyroptosis by inducing mitochondrial damage in mice and AML-12 cells. J Hazard Mater. 2024;467:133719.38335615 10.1016/j.jhazmat.2024.133719
172. Briand F Heymes C Bonada L Angles T Charpentier J Branchereau M A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death Clin Transl Sci 2020 13 529 38 10.1111/cts.12735 31981449
Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, et al. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. Clin Transl Sci. 2020;13:529–38.31981449 10.1111/cts.12735
173. Tong J Lan XT Zhang Z Liu Y Sun DY Wang XJ Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis Acta Pharmacol Sin 2023 44 1014 28 10.1038/s41401-022-01010-5 36323829
Tong J, Lan XT, Zhang Z, Liu Y, Sun DY, Wang XJ, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Acta Pharmacol Sin. 2023;44:1014–28.36323829 10.1038/s41401-022-01010-5
174. Tian Z Jiang S Zhou J Zhang W Copper homeostasis and cuproptosis in mitochondria Life Sci 2023 334 122223 10.1016/j.lfs.2023.122223 38084674
Tian Z, Jiang S, Zhou J, Zhang W. Copper homeostasis and cuproptosis in mitochondria. Life Sci. 2023;334:122223.38084674 10.1016/j.lfs.2023.122223
